Drug, bio-affecting and body treating compositions inventions 04/08

20080095699 - Imaging contrast agents using nanoparticles: The present invention relates to a nanoparticle comprising self-assembled crosslinked, amphiphilic block copolymers and at least one immobilized dye, wherein the self-assembled, crosslinked, amphiphilic block copolymers comprise a hydrophilic block and a hydrophobic block, wherein the self-assembled, crosslinked, amphiphilic block copolymers are self-assembled to form a core of the nanoparticle... Agent: Patent Legal Staff Eastman Kodak Company

20080095704 - Imaging agents with improved pharmacokinetic profiles: The invention relates to compounds suitable for use in an imaging agent said imaging agent showing an improved pharmacokinetic profile.... Agent: Ge Healthcare, Inc.

20080095703 - Method for checking and controlling the mammalian lactic acid fermentation process / aerobic glucose fermentation metabolic pathway in mammalian organism: The method for qualitative and quantitative detecting of the extend of use and the correct process flow of the mam- malian aerobic glucose fermentation metabolic pathway (mam-aGF) in a mammalian individual is characterized in that the enzyme TKTL1 is used as indicator and target molecule and that the structural and/or... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20080095713 - Method of tumour imaging: The invention relates to a method of producing a composition comprising hyperpolarised 13C-pyruvate, the composition and its use as an imaging agent for MR imaging.... Agent: Ge Healthcare, Inc.

20080095715 - Peptide based-compounds: The invention relates to new peptide-based compounds and their use in diagnostic optical imaging techniques. More specifically the invention relates to the use of such peptide-based compounds as targeting vectors that bind to receptors associated with angiogenesis. The compounds are labelled with at least one cyanine dye reporter and may... Agent: Ge Healthcare, Inc.

20080095720 - Skin benefit compositions with a vanilloid receptor antagonist: Compositions that benefit skin and that reduce irritation of the skin are described. The compositions have a skin benefit agent like a hydroxy acid and a vanilloid receptor antagonist. The compositions of this invention can reduce wrinkles on the skin when applied, and they can be formulated to contain glycolic... Agent: Unilever Intellectual Property Group

20080095726 - Aqueous fatty monoamine-containing systems for water-insoluble materials: The present invention is drawn to an aqueous composition containing: (a) at least one fatty monoamine; (b) at least one nonionic surfactant; (c) at least one compound chosen from an alkyl ether carboxylic acid, an alkyl ether carboxylate, a fatty acid having from about 6 to about 40 carbon atoms,... Agent: L'oreal Usa/ Patent Department

20080095729 - Aqueous fatty quaternary amine-containing systems for water-insoluble materials: The present invention is drawn to an aqueous composition containing: (a) at least one fatty quaternary amine; (b) at least one nonionic surfactant; (c) at least one compound chosen from an alkyl ether carboxylic acid, an alkyl ether carboxylate, a fatty acid having from about 6 to about 40 carbon... Agent: L'oreal Usa/ Patent Department

20080095725 - Aqueous phospholipid-containing systems for water-insoluble materials: The present invention is drawn to an aqueous composition containing: (a) at least one phospholipid; (b) at least one nonionic surfactant; (c) at least one compound chosen from an alkyl ether carboxylic acid, an alkyl ether carboxylate, a fatty acid having from about 6 to about 40 carbon atoms, and... Agent: L'oreal Usa/ Patent Department

20080095727 - Aqueous systems containing fatty monoamine, surfactant and phosphate ester for water- insoluble materials: The present invention is drawn to an aqueous composition containing: (a) at least one fatty monoamine compound; (b) at least one nonionic surfactant; (c) at least one phosphate ester chosen from alkoxylated alkyl phosphate esters and alkyl phosphate esters; and (d) at least one water-insoluble material, and wherein the composition... Agent: L'oreal Usa/ Patent Department

20080095728 - Aqueous systems containing polyamine, surfactant and phosphate ester for water-insoluble materials: The present invention is drawn to a aqueous composition containing: (a) at least one polyamine compound having at least three amino groups; (b) at least one nonionic surfactant; (c) at least one phosphate ester chosen from alkoxylated alkyl phosphate esters and alkyl phosphate esters; and (d) at least one water-insoluble... Agent: L'oreal Usa/ Patent Department

20080095730 - Volumizing compositions: The invention relates to compositions for keratin materials (hair or eyelashes) such as mascaras, topcoats and basecoats containing (a) at least one phosphate surfactant; and (b) at least one polyamide resin.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080095742 - Composition for treating virus infection disease comprising jab1: Disclosed is a composition for treating or preventing a viral infection or associated disease comprising a Jab1 protein, a nucleic acid having a nucleotide sequence coding for a Jab1 protein or a recombinant virus expressing a jab1 protein.... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20080095752 - Method for extending the shelf-life of powdered nutritional formulations which contain viable probiotics: The invention involves a method for extending the shelf life of a powdered nutritional formulation that contains LGG by reducing and maintaining a threshold water activity or moisture content in the powdered LGG-containing formulation.... Agent: Bristol-myers Squibb Company - Mead Johnson

20080095748 - Cellular scaffold: A cellular scaffold that is suitable for tissue regeneration, cell culture and in vitro assays. The invention relates to a layered cell scaffold that is seeded with mesenchymal and ectodermal cells. The layered cellular scaffold comprises an inoculum of mesenchymal cells and ectodermal cells positioned between two opposing scaffolds in... Agent: Stemedica Cell Technologies, Inc

20080095746 - Process for producing hematopoietic stem cells or vascular endothelial precursor cells: The present invention provides methods for producing hematopoietic stem cells or vascular endothelial precursor cells, wherein the methods comprise the step of separating PCLP1-positive cells from the hematopoietic tissues of an individual, and then culturing the obtained cells. PCLP1-positive cells obtained from the hematopoietic tissues of an individual can be... Agent: Ann-louise Kerner Wilmer Cutler Pickering Hale And Dorr

20080095754 - Ophthalmic compositions comprising diglycine: An ophthalmic composition that includes an epithelium cell stabilizer component. The epithelium cell stabilizer component may be one or more of diglycine, triglycine, tetraglycine, pentaglycine. The invention is also directed to a method of treating or preventing dry eye comprising administering an effective amount of the ophthalmic composition to the... Agent: Joseph Barrera Bausch & Lomb Incorporated

20080095757 - Vitamin c compositions: The field of invention relates to Vitamin C compositions, and in particular to Vitamin C compositions containing ascorbate-glucose transport enhancers. In at least one aspect, a composition is provided herein that includes ascorbate in an amount from about 0.1% by weight of actives to about 99.9% by weight of actives,... Agent: Patent Group C/o Dla Piper US LLP

20080095700 - Dr4 antibodies and uses thereof: Death Receptor 4 (DR4) antibodies are provided. The DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided.... Agent: Sidley Austin LLP Attn: Dc Patent Docketing

20080095701 - Diagnostic compounds: The invention relates to conjugates of formula (III) or (IIIa), or a salt thereof, their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes.... Agent: Ge Healthcare, Inc.

20080095702 - Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid: The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty... Agent: Edwards Angell Palmer & Dodge LLP

20080095708 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such... Agent: Theravance, Inc.

20080095707 - Ca ix-specific inhibitors: Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably membrane-impermeant compounds, which inhibit the enzymatic activity of MN protein/polypeptides and that are useful for treating patients with preneoplastic/neoplastic disease. Further methods are disclosed for... Agent: Leona L. Lauder Attorney At Law

20080095709 - Method and apparatus for installation of dental implant: An organ derived from genetic material is inserted in a patient's body. Genetic material is inserted at a selected site in the body to grow an organ.... Agent: Gerald K. White, Esq. Gerald K. White & Associates, P.C.

20080095705 - Methods and devices for facile fabrication of nanoparticles and their applications: The invention provides devices and methods to fabricate nanoparticles by reverse micelle method. The method allows to fabricate a myriad of high quality nanoparticles in a repeatable way. These nanoparticles include multilayered spherical and rod like particles that may have inorganic, organic, polymeric, biological layers. The invention further provides methods... Agent: Fildes & Outland, P.C.

20080095706 - Peptide probes for diagnostics and therapeutics: Disclosed are agents and methods that may be used to diagnose and treat a variety of diseases associated with conformationally-altered proteins. The agents and methods may be used to identify and deliver drugs useful for treating diseases associated with conformationally-altered proteins.... Agent: Foley And Lardner LLP Suite 500

20080095710 - Enzyme treatment of foodstuffs for celiac sprue: Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.... Agent: Bozicevic, Field & Francis LLP

20080095711 - Modulators of pulmonary hypertension: Compounds, compositions, and methods for inhibiting pulmonary hypertension are disclosed. The invention is particularly directed to the use of agents that specifically inhibit the activity of certain endogenously produced epoxyeicosatrienoic acids that promote vasoconstriction of pulmonary arteries. These agents are particularly useful for inhibiting hypoxia-induced pulmonary hypertension. The invention further... Agent: Thompson Coburn, LLP

20080095712 - Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in living organisms: An object of the present invention is to develop a new alternative splicing reporter system and to provide a method for detecting alternative splicing patterns in a multicellular organism more precisely, a method for identifying efficiently substances and gene regions that affect alternative splicing in a multicellular organism, and the... Agent: Arthur G. Schaier Carmody & Torrance LLP

20080095714 - Method and apparatus to identify vulnerable plaques with thermal wave imaging of heated nanoparticles: Provided herein are systems, methods, and compositions for the thermal imaging of cells with nanoparticles.... Agent: Rosenbaum & Associates, P.C.

20080095716 - Use in the medical, diagnostic and phlebological field of a mixture of sterile and physiologically acceptable purposes: The present invention relates to a mixture of sterile and apyrogenic gases based on CO2 and O2 suitable for producing microbubbles which can be used in the medical, phlebological and diagnostic field. The gas mix allows stable and physiologically acceptable microbubbles to be formed, by means of more standardized procedures... Agent: James V Costigan Hedman & Costigan

20080095717 - Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics: A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in... Agent: Chiron Corporation Intellectual Property - R440

20080095718 - Methods and compositions for treating erectile dysfunction: Methods are provided for increasing libido and/or treating erectile dysfunction in a man. The methods include the administration of a formulation testosterone alone, another fast-acting drug to treat erectile dysfunction or a combination of the testosterone and the other drug where at least one is delivered by aersolization. The formulation... Agent: Bozicevic, Field & Francis LLP

20080095719 - Blackberry extract: The invention concerns a blackberry leaf extract and its uses, in particular to slow down skin ageing, to treat the oral and pharyngeal cavity, and there in particular to prevent and slow down periodontitis and the excessive degradation of the periodontal connective tissue as well as damage to the teeth... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20080095721 - Natural sunscreen compositions and processes for producing the same: Disclosed is a natural sunscreen composition comprising extracts of Hedychium spicatum and/or Alpinia galanga containing active sunscreen agents, the sunscreen composition devised to protect the skin from the harmful effects of short wavelength UV B rays and long wavelength UV A rays.... Agent: Knobbe Martens Olson & Bear LLP

20080095722 - Extended surface aggregates in the treatment of skin conditions: The invention relates to the use of extended surface aggregates (ESAs) comprising at least one first amphipathic component, which is a basic aggregate-forming component, and at least one second amphipathic component, which decreases aggregate sensitivity to physical stress, including stress created by enforced passage of said ESAs through pores with... Agent: Wilson Sonsini Goodrich & Rosati

20080095723 - Cosmetic composition: e

20080095724 - Pulverulent cosmetic formulation having a high water content: Pulverulent cosmetic formulation comprising at least one hydrophobized silicon dioxide powder, at least one cosmetically relevant constituent and at least 50 wt. % of water, based on the total amount of the formulation, characterized in that the hydrophobized silicon dioxide powder has a tamped density of at least 70 g/l,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080095731 - Personal care compositions comprising alpha-glucans and/or beta-glucans: Personal care compositions containing at an alpha-glucan and/or beta-glucan; at least one additional skin and/or hair care active selected from the group consisting of sugar amine, vitamin B3, retinoids, peptides, phytosterol, dialkanoyl hydroxyproline, hexamidine, salicylic acid, n-acyl amino acid compounds, sunscreen actives, water soluble vitamins, oil soluble vitamins, hesperedin, mustard... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080095732 - Personal care compositions: Personal care compositions comprising a dipeptide; one or more of the following: a pentapeptide, a second dipeptide, a vitamin B3 compound, a hexamindine compound, and/or a sugar amine; and a dermatologically acceptable carrier. Methods of using such compositions to treat the condition of keratinous tissue. In certain embodiments, the C... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080095733 - Structured surfactant system: An aqueous structured surfactant composition contains an anionic surfactant selected from isethionate surfactants, taurate surfactants, and sarcosinate surfactants, and mixtures thereof, and an electrolyte and is useful in personal care applications.... Agent: Kevin E. Mc Veigh Rhodia Inc.

20080095734 - Chemical formulation and process for de-cuticleizing hair strands: Embodiments of the present invention are directed to a chemical formulation for de-cuticleizing hair strands comprising boiled water, bleach, shampoo, conditioner, and botanical oil, wherein the shampoo comprises a silicon based composition.... Agent: Dinsmore & Shohl LLP

20080095735 - Skin-protective polymer for use in teat care compositions: This invention relates generally to the field of antimicrobial teat care compositions. More particularly, it relates to a skin-adhering antimicrobial composition comprising a copolymer which contains methacrylic acid and 2-acrylamido-2-methyl-propane sulfonic acid (AMPS) monomeric units, the antimicrobial composition hindering the transfer of bacteria from the environment to underlying teat surfaces... Agent: Coleman Sudol Sapone, P.C.

20080095736 - Biocompatible polymers and hydrogels and methods of use: Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable or not are provided, as... Agent: Dardi & Associates, PLLC US Bank Plaza

20080095737 - Non-toxic coating composition, methods of use thereof and articles protected from attachment of biofouling organisms: Antifouling coating compositions and methods are disclosed, in which the active agent is preferably (−)trans-p-menthane-3,8-diol, (−)-menthol, (−)-menthyl chloride, menthoxypropanediol, (−)-isopulegol or (−)-menthone.... Agent: Akerman Senterfitt

20080095739 - Heterocyclic antiviral compounds: Compounds having the formula Ia or Ib wherein R1, R2, R3 and R4 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20080095740 - Piperidine derivatives useful as ccr5 antagonists: or a pharmaceutically acceptable salt or solvate thereof, wherein the various moieties are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080095738 - Vlp-antigen conjugates and their uses as vaccines: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising a virus-like particle (VLP) of an RNA-bacteriophage and at least one antigen, wherein the VLP is recombinantly produced in a host, and wherein the amount of host RNA with... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080095741 - R-(+)-alpha-liponic acid for the prevention of diabetes: The invention relates to the use of R-(+)-α-lipoic acid in oxidised or reduced form or derivatives thereof alone or in combination with other effective compounds for the prevention of diabetes.... Agent: Venable LLP

20080095744 - Methods and compositions for cytokine expression and treatment of tumors: A conditionally replicating, aneurovirulent recombinant herpes simplex virus is provided that includes a nucleic acid encoding an expressible chemokine. An expression control element is operably linked to the nucleic acid. A therapeutic composition includes a first conditionally replicating, aneurovirulent recombinant herpes simplex virus having a first nucleic acid encoding a... Agent: Gifford, Krass, Sprinkle, Anderson & Citkowski, P.C.

20080095743 - Monoclonal antibody that specifically binds stem cells and its use: Antibodies are disclosed herein that bind Spoc cells. In one embodiment the antibodies are monoclonal antibodies. The use of antibodies that bind Spoc cells to identify and/or isolate a sub-population of Spoc cells is also disclosed. In one embodiment, a method for treating a neurologic disorder is provided. The method... Agent: Klarquist Sparkman, LLP

20080095751 - Atherosclerosis: The present invention relates, in general, to atherosclerosis and, in particular, to a method of treating atherosclerosis and to cells suitable for use in such a method.... Agent: Nixon & Vanderhye, PC

20080095745 - Novel strain conferring anti-disease properties to host and bacterial cell composition: The present invention provides a novel bacterial cell composition which comprises cells of Butyrivibrio fibrisolvens having the ability to produce butyric acid, a cultured material thereof or an extract thereof, and a method for inhibiting carcinogenesis, a method for immunostimulating, a method for preventing or treating a pathogen, a method... Agent: Sughrue-265550

20080095749 - Mesenchymal stem cells and uses therefor: Methods of treating autoimmune diseases, allergic responses, cancer, inflammatory diseases, or fibrosis in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.... Agent: Carella, Byrne, Bain, Gllfillan, Cecchi, Stewart & Olstein

20080095747 - Promotion of cell migration and axon regeneration in the cns: The present invention relates broadly to methods for stimulating neural progenitor cell migration to certain regions of the nervous system where the neural progenitor cell naturally would not migrate. These methods have wide interest in fields related to the development of therapeutic approaches for addressing a broad range of neurodegenerative... Agent: Proteus Patent Practice LLC

20080095750 - Use of adipose-derived stem cells for treatment of leukodystrophies: The present invention relates to a treatment of a leukodystrophy by administration of an adipose-derived stem cell. Specifically, the present invention relates to the treatment of Krabbe disease with an adipose derived stem cell differentiated to express galactocerebrosidase.... Agent: Seed Intellectual Property Law Group PLLC

20080095753 - Pharmacological vitreolysis: Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited... Agent: Wilmerhale/boston

20080095755 - Methods and compositions for the treatment of cancer: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.... Agent: Casimir Jones, S.c.

20080095756 - Compositions comprising lysostaphin variants and methods of using the same: The present invention relates to compositions comprising lysostaphin variants and methods of using the same. In particular, the present invention provides de-immunized lysostaphin variants and methods of using the same (e.g., to treat microbial infection in or on a subject).... Agent: Casimir Jones, S.c.

20080095758 - Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes... Agent: Law Office Of Michael A. Sanzo, LLC

20080095759 - Defense and counter-defense compositions and methods: Contemplated compositions and methods are directed to the use of a proteinase to reduce capsaicin-induced pain sensation in a mammal. Preferably, the proteinase comprises a bromelain preparation in a liquid formulation for topical or enteral administration. In additional aspects of the inventive subject matter, a proteinase inhibitor is present in... Agent: Fish & Associates, PC Robert D. Fish

20080095760 - Methods of treating stroke: A method is provided for the localized intravascular administration of a fibrinolytic metalloproteinase to a human subject in amounts that are both safe and effective to lyse an occluding fibrin-containing blood clot, while also avoiding the neutralizing effects of α2-macroglobulin in the circulating blood. A method is also provided for... Agent: Robins & Pasternak

20080095761 - Hedgehog signaling in prostate regeneration neoplasia and metastasis: Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in prostate tumors, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating a prostate cancer associated with elevated Hh pathway activity by reducing or inhibiting the Hh... Agent: Dla Piper US LLP

20080095763 - Cdk9 as modifier of the igf pathway and methods of use: Human CDK9 genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of CDK9 are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20080095762 - Glycoprotein compositions: The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin.... Agent: Heller Ehrman LLP

20080095765 - Il-5r-specific antibody composition: The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human interleukin-5 receptor α chain and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in... Agent: Nixon & Vanderhye, PC

20080095764 - Use of genetically-and epigenetically-altered protocadherins in methods of diagnosing, prognosing, and treating cancer: The present invention provides methods for determining whether a subject has neoplasia, for assessing the efficacy of therapy to treat neoplasia in a subject who has undergone or is undergoing treatment for neoplasia, and for assessing the prognosis of a subject who has neoplasia. The present invention further provides kits... Agent: Wilmerhale/columbia University

20080095772 - Antibodies against human parathyroid hormone related protein: Disclosed are an antibody against human para-thyroid-hormone-related protein, a DNA coding for the antibody, a recombinant vector containing the DNA, a transformant transformed with the recombinant vector, a method for preparation of the antibody, and uses of the antibody.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080095770 - Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080095767 - Engineered antibodies with new world primate framework regions: The present invention provides an antibody or antigen-binding portion thereof having a variable region comprising at least two complementarity determining regions (CDRs) and at least three framework regions. The the framework regions are, or are derived from New World primate framework regions, and at least one of the CDRs is... Agent: Morrison & Foerster LLP

20080095769 - Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies,... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080095766 - Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity: The present invention provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of T cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes (i.e. type 1 diabetes or insulin-dependent diabetes mellitus (IDDM)) and multiple sclerosis) through the use of anti-human CD3 antibodies. The antibodies of... Agent: King & Spalding

20080095773 - Polypeptides homologous to vegf and bmp1: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be... Agent: Genentech, Inc.

20080095771 - Treatment method: The invention provides methods of treating autoimmune diseases using lower doses of anti-CD20 antibodies effective to deplete B cells in the patient.... Agent: Genentech, Inc.

20080095768 - Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells: Methods for treating MM using anti-CS1 antibodies are provided herein.... Agent: Pdl Biopharma, Inc. Attn: Legal Department

20080095774 - Agents and methods for specifically blocking cd28-mediated signaling: The instant invention provides compositions and methods for downmodulation of immune responses, e.g., autoimmune responses. For example, methods of downmodulating an immune response using agents that specifically block CD28-mediated signaling are provided. The subject methods are useful for both prophylactic and therapeutic downmodulation of immune responses.... Agent: Foley Hoag, LLP/wyeth Patent Group, (w/wys)

20080095775 - Il-17 and il-23 antagonists and methods of using the same: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.... Agent: Zymogenetics, Inc. Intellectual Property Department

20080095776 - Erythropoietin receptor binding antibodies: The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions containing said antibodies.... Agent: Dykema Gossett PLLC

20080095780 - Binding molecules for treatment and detection of cancer: The present invention provides new tumor-associated antigens, binding molecules that specifically bind to the antigens, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The new tumor-associated antigen are expressed on cancer cells and binding molecules capable of... Agent: Trask Britt

20080095781 - Dr4 antibodies and uses thereof: Death Receptor 4 (DR4) antibodies are provided. The DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided.... Agent: Sidley Austin LLP Attn: Dc Patent Docketing

20080095777 - Immunogenic composition for use in vaccination against staphylococcei: The present application relates to immunogenic compositions comprising a mixture of staphylococcal antigens which combines antigen having different functions, for instance, combinations including a staphylococcal extracellular component binding protein and a staphylococcal transporter protein or a staphylococcal extracellular component binding protein and a staphylococcal regulator of virulence or toxin or... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080095779 - Runx2 isoforms in angiogenesis: The present invention relates to RUNX2 and RUNXdelta8, and their use in modulating conditions and diseases associated with angiogenesis and cell proliferation. For example, RUNX2delta8 can be utilized to inhibit tumor growth and to prevent or inhibit angiogenesis. The present invention also relates to antibodies which specifically recognize RUNX2delta8, and... Agent: Millen, White, Zelano & Branigan, P.C.

20080095778 - Treatment of fungal infections: A composition comprising an antibody or an antigen binding fragment thereof specific for at least one epitope of hsp90 from an organism of the Aspergillus genus, and at least one antifungal agent selected from the group consisting of: itraconazole and voriconazole.... Agent: Fish & Richardson PC

20080095782 - Use of lipocalin-2 as a diagnostic marker and therapeutic target: Methods and compositions for identifying and treating obesity and obesity-induced metabolic disorders are provided. One aspect provides a method for the evaluation of risk and progression of glucose tolerance, insulin resistance and Type 2 diabetes in mammalian subjects. The method includes measuring the concentration of circulating lipocalin-2 in a subject... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080095783 - N-glycosylated antibody: The invention relates to a monoclonal antibody or derivative or fragment thereof that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region or region equivalent to the Fc region of said antibody or derivative or fragment thereof carries a bi-sected... Agent: Birch Stewart Kolasch & Birch

20080095784 - Human monoclonal antibodies to fc gamma receptor l (cd64): The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to CD64 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the... Agent: Lahive & Cockfield, LLP

20080095785 - Monoclonal antibodies to human high molecular weight-melanoma associated antigen: The present invention provides monoclonal antibodies that react against high molecular weight melanoma-associated antigen. These antibodies may be used for diagnostic and/or therapeutic purposes.... Agent: Wyeth C/o Darby & Darby, P.C.

20080095787 - Adjuvants and methods of use: Compositions comprising NKT cell agonist compounds and a physiologically acceptable vehicle are provided. Methods of stimulating an NKT cell and enhancing an immune response are also disclosed. Further provided are vaccine preparations comprising NKT cell agonist compounds.... Agent: Michael Best & Friedrich LLP

20080095786 - Compositions and methods for preventing and treating endotoxin-related diseases and conditions: The invention provides pharmaceutical compositions for preventing and treating endotoxin-related diseases and conditions, as well as methods for making and using such compositions.... Agent: Clark & Elbing LLP

20080095788 - Vaccines: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080095789 - Vaccine: A vaccine for preventing formation of blood vessels, for example neoangiogenesis, as well as repressing existing vascularization associated with tumors and other diseases, comprising angiomotin, for example as a whole molecule or fragment thereof or encoded as a gene or mRNA, or administered as dendritic cells (DC cells) expressing angiomotin,... Agent: Kenyon & Kenyon LLP

20080095790 - Methods of treating prostate cancer: A method of treating prostate cancer in a human using a prostate-specific antigen peptide vaccine and a dosing regimen for administering said vaccine is provided.... Agent: Marshall, Gerstein & Borun LLP

20080095791 - Recombinant hiv-1 gp120 immunogen with three different v3 loops from viruses of different clades: A novel immunogenic HIV-1 Env, particularly gp120, DNA construct is disclosed in which either the V1/V2 loop and the V4 loop, or all three variable loops, including V3, are replaced with a V3 sequence each of which is from a different viral isolate. Preferably, each replacement V3 loop is a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080095793 - Chlamydia flagellar protein antigen: The present invention provides purified and isolated polynucleotide molecules that encode Chlamydia polypeptides which can be used in methods to prevent, treat, and diagnose Chlamydia infection. In one form of the invention, the polynucleotide molecules encode polypeptides CPN100988 RY-68 (SEQ ID Nos:13 and 26).... Agent: Smart & Biggar P.o. Box 2999, Station D

20080095792 - Polypeptides for inducing a protective immune response against staphylococcus aureus: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full length S. aureus polypeptide. The full-length polypeptide is based on full-length SA0024. A His-tagged derivative of SEQ... Agent: Merck And Co., Inc

20080095794 - Recombinant bcg strains with enhanced ability to escape the endosome: Mycobacterium strains that have an enhanced ability to elicit a MHC-Class I-restricted CD8+ T cell immune response are provided. The Mycobacterium strains are genetically engineered to express: a endosomolytic protein that is active at neutral pH (e.g. Perfringolysin O), permitting escape of the Mycobacterium from endosomes into the cytoplasm of... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080095795 - Composition comprising iscom particles and live micro-organisms: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at... Agent: Albihns Stockholm Ab

20080095798 - Ii-key enhanced vaccine potency: Disclosed is a method for increasing vaccine potency whereby a subject's immune system is first primed with an Ii-Key hybrid peptide construct before the subject subsequently receives a vaccine for a pathogen of interest. The vaccine may be comprised of a protein or portion thereof that is encoded by the... Agent: Kevin M. Farrell Pierce Atwood

20080095796 - Novel infectious burasal disease virus and vaccine containing said virus: Novel infectious bursal disease (IBD) virus not protectable by the conventional IBD vaccines was isolated and a novel vaccine efficacious to said virus is provided. Novel IBD virus TY2 strain was isolated and its passage strains were obtained. TY2 strain has a distinct genetic type from those of the known... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080095797 - Recombinant marek's disease virus: The present invention relates to a Marek's disease virus having a mutation in one or both Meq genes thereof such that the virus is non-pathogenic. The present invention also relates to a vaccine comprising such a virus, and the use of the virus in medicine.... Agent: Brooks Kushman P.C.

20080095799 - Apparatus for vaccine development using ultrasound technology: Method and device for the creation of vaccines using ultrasonic waves, comprised of an ultrasound generator and a transducer to produce ultrasonic waves, is disclosed. The transducer has a specific ultrasound tip depending upon the type of delivery method utilized and depending on the shape of the vial containing the... Agent: Bacoustics, LLC

20080095800 - Eliciting hcv-specific antibodies: Described herein is a method of eliciting antibodies and neutralizing of binding antibodies against a hepatitis C virus (HCV) E1E2 or E2 antigen using HCV E2 or HCV E1E2 polypeptides and/or HCV E2 or E1E2 polynucleotides. Elicitation of anti-E2 antibodies and anti-E2 NOB antibodies can be used, inter alia, to... Agent: Novartis Vaccines And Diagnostics Inc.

20080095801 - Homeopathic agent for the prophylaxis of diseases caused by parasites and method of producing and using the homeopathic agent: A homeopathic agent containing Ledum palustre in the form of a homeopathic dilution in an inert carrier material and at least one secretion from a parasite, a sufferer of a disease caused by parasites, or from an intermediate host in the form of a homeopathic dilution in an inert carrier... Agent: Lerner Greenberg Stemer LLP

20080095802 - Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients iwth transplanted organs, b) as radiosensitizers to cancer cells in paients undergoing radiation therapy, and c) in vitaminpbinding proteins as drug carriers in the diagnosis and: This invention relates to the targeted delivery of cytotoxic drugs A) to lymphocytes responsible for the rejection of transplanted tissues, such as kidneys or hearts or bone marrow cells; B) the use of a non-toxic naturally existing delivery system to transport high concentrations of radiosensitizers to cancer cells; and C)... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080095803 - Protein matrix vaccines and methods of making and administering such vaccines: The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.... Agent: Clark & Elbing LLP

20080095804 - Two-step immunization procedure against chlamydia infection: A host is immunized against infection by a strain of Chlamydia by initial administration of an attenuated bacteria harbouring a nucleic acid encoding a Chlamydia protein followed by administration of a Chlamydia protein in ISCOMs. This procedure enables a high level of protection to be achieved.... Agent: Sim & Mcburney

20080095805 - Method of detecting cancer based on immune reaction to boris: The invention provides a method comprising detecting autoantibodies to BORIS in a sample obtained from a mammal, as well as BORIS polypeptides and epitopes, and kits comprising the BORIS polypeptides and epitopes, and a method of inducing an immune response to BORIS in a mammal.... Agent: Leydig, Voit & Mayer, Ltd.

20080095806 - Composition and method for treating inflammatory diseases using protease inhibitors: Compositions containing a protease inhibitor and methods of use and production are described. The compositions contain an effective amount of a protease inhibitor in a carrier or diluent and are used for the treatment of inflammatory or hyperproliferic mucocutaneous disorders. The carrier or diluent is preferably a gelling agent, and... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080095809 - Composition for a clear cosmetic stick: The present invention includes a clear cosmetic stick that has a clarity that is stable over a temperature of 5 to 45 degrees Centigrade for a time period of at least about twelve months. The clear cosmetic stick includes one or more of a branched chain fatty acid surfactant and... Agent: Schwegman, Lundberg & Woessner, P.A.

20080095808 - Cosmetic candle: A cosmetic candle comprising tiny grains embedded therein. The grains impart a mechanical property that can be exploited for scrubbing skin to peel off old or dead tissue with a concomitant massaging of molten waxes into the skin. Crushed pits and seeds of olives, apricots, peaches, citrus fruits and/or plums... Agent: Edwin Tarver

20080095807 - Cosmetic soap: A cosmetic soap composed of soap matrix and skin beneficial agents. The soap produced by a process comprising the steps of: storing and maintaining the previously prepared molten soap matrix in a first container at a first predetermined temperature, storing and maintaining the previously prepared beneficial agents in a second... Agent: Edwin Tarver

20080095811 - Methods of bleaching teeth using adhesive dental bleaching compositions containing polyvinylpyrrolidone: A dental bleaching composition comprises a dental bleaching agent and a polyvinylpyrrolidone thickening agent. The bleaching composition may include water, flavoring agents, a basic substance and desensitizing agents, as desired. Polyvinylpyrrolidone avoids acid etching and chelation of teeth that were problematic in bleaches using carbomer as a thickener. A delivery... Agent: Workman Nydegger

20080095810 - Nanoparticles of chitosan and polyethyleneglycol as a system for the administration of biologically-active molecules: The present invention relates to nanoparticle systems for the release of biologically active molecules formed by the chitosan polymer or its derivatives, chemically modified with polyethylene glycol and crosslinked with a crosslinking agent. These systems are especially useful for pharmaceutical compositions, vaccines and cosmetic formulations.... Agent: Intellectual Property / Technology Law

20080095812 - Systems providing antimicrobial activity to an environment: A process reduces the microbial content in land mass by providing molecular iodine in the land mass in a concentration in aqueous material in the land mass of at least 5 or 10 parts per million. The molecular iodine may be added in gaseous or liquid or solid state, and... Agent: Mark A. Litman & Associates, P.A.

20080095813 - Insect control and elimination method and composition: A method and composition of controlling and eliminating insects is provided. The method and composition of eliminating sophisticated chemical communication systems between insects is enhanced where insects live in functional groups, such as swarms, nests, colonies, hives, breeding pools, mounds, mating areas and other interdependent social groups. An odor neutralizer... Agent: Alton W. Payne

20080095814 - Compositions having a high antiviral and antibacterial efficacy: Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness are disclosed. The antimicrobial compositions contain a phenolic antimicrobial agent, a surfactant, a hydrotrope, and a disinfecting alcohol, wherein the phenolic antimicrobial agent is present in a continuous aqueous phase in an amount of at least 25% of saturation concentration.... Agent: Marshall, Gerstein & Borun LLP (dial)

20080095816 - Compositions and devices comprising silicone and specific polyphosphazenes: The present invention relates to compositions and medical devices comprising both polyorganosiloxane and polyphosphazene compounds. When incorporated into or onto medical devices, these compositions reduce cell encrustation on the device and reduce the severity of thrombosis when the devices are in contact with body fluids, and impart anti-rejection properties to... Agent: Sutherland Asbill & Brennan LLP

20080095815 - Hollow and porous orthopaedic or dental implant that delivers a biological agent: This invention relates to the synthesis of new tooth or bone from an encapsulated biological agent such as a growth factor or stem cells contained within a hollow and porous biocompatible vehicle such as a titanium implant placed (implanted) within the body of a host animal such as a human.... Agent: Barnes & Thornburg LLP

20080095817 - Multilayer tissue regeneration system: A system for growing tissue based upon layers of an inorganic matrix, wherein each layer of the inorganic matrix is designed to dissolve at a separate rate and result in sequential growth factor delivery upon its dissolution.... Agent: Quarles & Brady LLP

20080095819 - Composition and methods for promoting wound healing and tissue regeneration: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.... Agent: Needle & Rosenberg, P.C.

20080095820 - Method of manufacturing hydroxyapatite and uses therefor in delivery of nucleic acids: Provided is a method for production of nanocrystalline hydroxyapatite particles, and nanocrystalline hydroxyapatite particles produced according to the method. The nanocrystalline hydroxyapatite particles exhibit substantially superior cell transformation abilities as compared to known and commercially-available calcium phosphate kits. The nanocrystalline hydroxyapatite particles also find use in tissue engineering applications, for... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20080095821 - Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response: This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable... Agent: Beyer Weaver LLP

20080095818 - Tubular structure based on hyaluronic acid derivatives for the preparation of vascular and urethral graft: Tubular structure, whose wall has an unbroken surface consisting essentially of at least one HA derivative and optionally a further polymer of natural, synthetic or semisynthetic origin. Said tubular structure, which is prepared with a very simple process, is used for the preparation of vascular and urethral grafts.... Agent: Abelman, Frayne & Schwab

20080095822 - Active substance delivery system comprising a hydrogel atrix and microcarriers: Active substance delivery system, comprising a biocompatible and biostable hydrogel matrix, and biodegradable microcarriers which are homogenously embedded within the hydrogel matrix, and contain at least two active substances.... Agent: Jacobson Holman PLLC

20080095824 - Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space: The present invention provides delivery of drugs to the heart or cardiac vasculature using fully implanted sustained-release dosage forms.... Agent: David J. Abraham Durect Corporation

20080095823 - Medical devices and applications of polyhydroxyalkanoate polymers: Devices formed of or including biocompatible polyhydroxyalkanoates are provided with controlled degradation rates, preferably less than one year under physiological conditions. Preferred devices include sutures, suture fasteners, meniscus repair devices, rivets, tacks, staples, screws (including interference screws), bone plates and bone plating systems, surgical mesh, repair patches, slings, cardiovascular patches,... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080095825 - Method for making a reservoir containing an active substance diffused through the reservoir and installation therefor: The invention concerns a method for making a reservoir (5) containing an active substance and adapted to be introduced into a natural cavity of a living being, the reservoir (5) comprising a membrane (9) permeable to the active substance. Said method includes steps which consist in: a) placing at least... Agent: James C. Lydon

20080095826 - Method of increasing peripheral blood lymphocytes: The present invention provides a method of increasing the lymphocyte count in peripheral blood and a method for stimulating the immune system in a subject, which include administering an effective amount of glutamic acid or a salt thereof to the subject. Since glutamic acid or a salt thereof is not... Agent: Cermak & Kenealy LLP Acs LLC

20080095827 - Nutritional weight loss agent and method: The present invention relates to an agent that suppresses appetite and provides quick energy. According to at least one aspect of the present invention, a lollipop is provided that suppresses appetite and provides quick energy. The lollipop is made from a premixed herbal formula that is combined with a hard... Agent: Brooks Kushman P.C.

20080095828 - Cleaning substrates with combinational actives: Various embodiments of the invention provide a method for treating a surface using a cleaning substrate. The cleaning substrate comprises a nonwoven web. The nonwoven web includes hydrophilic materials and chemical actives. The cleaning substrate provides a controlled release of the chemical actives on the surface to be cleaned. Additionally,... Agent: The Clorox Company

20080095829 - Antimicrobial composites, films, labelstocks and labels: This invention relates to antimicrobial composites, films, labelstocks and labels. The antimicrobial composites comprise a mixture of (A) a terpolymer prepared from a mixture comprising (i) an olefin, (ii) at least one copolymerizable comonomer comprising ethylenically unsaturated organic acids or esters, vinyl esters of saturated carboxylic acids and mixtures of... Agent: Armand P. Boisselle Renner, Otto, Boisselle & Sklar, LLP

20080095830 - Method for making a dressing: The present invention is directed to a method of making a dressing having at least one protein, comprising the steps of applying at least one protein to a dressing via conventional means; and further subjecting the dressing having the protein thereon to pressure ranging from about 2,500 to about 39,500... Agent: Philip S. Johnson Johnson & Johnson

20080095831 - Topical formulation of multilamellar vesicles composition for percutaneous absorption of pharmaceutically active agent: A composition of multilamellar vesicles for the delivery of pharmaceutically-active substances through the skin of a mammal, the composition including between about 1 to about 30% Cyclomethicone 5-.N.F., between about 1 to about 30% PEG-12 Dimethicone; between about 3 to about 14% Cyclopentasiloxane and PEG 12 Dimethicone Crosspolymers, between about... Agent: Fleit, Kain, Gibbons, Gutman, Bongini & Bianco P.l.

20080095836 - Glutathione-based delivery system: A delivery system. The delivery system includes a carrier having a surface, an active compound comprising small molecule compounds or peptides for use as an analgesic encapsulated into the carrier, and a glutathione or a glutathione derivative grafted on the surface of the carrier. The invention also provides a method... Agent: Birch Stewart Kolasch & Birch

20080095835 - Methods for treating cancers and restenosis with p21: The p21 gene encodes a cyclin dependent kinase inhibitor which affects cell cycle progression, but the role of this gene product in altering tumor growth has not been established. The present inventors have now discovered that the growth of malignant cells in vivo is inhibited by expression of p21. Expression... Agent: Brinks Hofer Gilson & Lione

20080095834 - Mitochondriotropic phospholipid vesicles: Mitochondriotropic phospholipid vesicles, i.e., mitochondriotropic liposomes, that comprise a hydrophobized amphiphilic delocalized cation, such as those comprising, e.g., a triphenylphosphonium or a quinolinium moiety, incorporated into the phospholipid membrane of the vesicles, or liposomes, are disclosed. The hydrophobized portion of the amphiphilic delocalized cation, e.g., a fatty acid or other... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20080095833 - Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides, and uses thereof: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polynucleotides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations... Agent: Novartis Vaccines And Diagnostics Inc.

20080095832 - Prosaposin as a neurotrophic factor: Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large, neurons of the brain, including both upper and lower motor neurons.... Agent: Kenyon & Kenyon LLP

20080095837 - Human growth hormone formulations: The present invention relates to dosage forms of human growth hormone, the use of an absorption enhancer to allow absorption of human growth hormone into the systemic circulation in a biologically active form, in particular after oral administration, as well as the use of oral dosage forms comprising human growth... Agent: Emisphere Technologies, Inc. C/o Darby & Darby P.C.

20080095838 - Solid pharmaceutical composition containing a lipophilic active principle and preparation method thereof: The invention relates to an orally-administered, solid pharmaceutical composition comprising, in a single same phase, a lipophilic active principle, a surface active agent, a cationic polymer which is insoluble in water at pH greater than or equal to 5 and a mineral or organic acid. The invention also relates to... Agent: Dickinson Wright PLLC

20080095839 - Controlled-release pharmaceutical composition and method for producing the same: It is an object of the present invention, in the case of a controlled-release pharmaceutical composition, particularly a pulsed-release pharmaceutical composition, containing an acid-unstable physiologically active substance, to provide a pharmaceutical composition having little variation in dissolution lag time and high reliability of dissolution characteristics. The present invention discloses a... Agent: Nixon & Vanderhye, PC

20080095840 - Nifedipine controlled release compositions and preparation methods therefor: A nifedipine controlled release composition is provided comprising a drug-layer and a push-layer at a ratio of 1:0.5˜3 by weight. The drug-layer contains nifedipine and 40˜99 percent by weight of the drug-layer of hydrophilic polyvinylpyrrolidone homopolymer and/or copolymer carrier. The push-layer comprises about 10 to 80 percent by weight of... Agent: Beyer Weaver LLP

20080095841 - Pharmaceutical composition, method for producing the same, and method for stabilizing dihydropyridine compound in the pharmaceutical composition: The present invention aims to provide a pharmaceutical composition containing a stable dihydropyridine compound, where improving the stability of dihydropyridine compounds in pharmaceutical compositions under influence of storage conditions and thus providing a pharmaceutical composition with superior handling ability and affordable administration. As such, the present invention is a pharmaceutical... Agent: Birch Stewart Kolasch & Birch

20080095844 - Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof: The present invention relates to sustained release pharmaceutical compositions comprising alfuzosin, a rate-controlling polymer and optionally one or more pharmaceutically acceptable excipients; process for preparing such compositions and method of using the compositions.... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20080095843 - Controlled-release formulations: Disclosed herein are controlled-release formulations which exhibit substantially zero-order release kinetics. The formulations include a core comprising a core active agent and a wax excipient substantially coated with an extended-release coating. The formulation optionally includes an immediate-release portion comprising an immediate-release active agent in the form of, for example, a... Agent: Cantor Colburn, LLP

20080095845 - Immediate release tablet: An immediate release tablet is provided. The tablet comprises at least 60 weight % of an active ingredient and powdered wax having a melting point greater than about 90° C. The tablet may advantageously be produced by direct compression. Although the wax is hydrophobic, the tablet has excellent disintegration.... Agent: Philip S. Johnson Johnson & Johnson

20080095842 - Rapidly disintegrating taste masked compositions and a process for its preparations: A resinate of Cetirizine or its pharmaceutically acceptable salts or its enantiomers or their salts such as Levocetirizine Dihydrochloride, fast disintegrating and or quick release pharmaceutical compositions containing the resinate and the process for the preparation of the said resinate and composition is disclosed. Preparation of resinate and composition comprising... Agent: Holland & Bonzagni, P.C.

20080095846 - Pharmaceutical compositions of antihistamine and decongestant: The present invention discloses a bilayer tablet composition comprising controlled or modified release decongestants such as pseudoephedrine or its salts or derivatives thereof with suitable pharmaceutical excipients with immediate release second layer comprising piperidinoalkanol compounds such as fexofenadine or its salts and derivatives thereof manufactured using just one functional excipient.... Agent: Bio Intellectual Property Services (bio Ips) LLC

20080095847 - Stimulus-release carrier, methods of manufacture and methods of treatment: Compositions, methods of fabrication and methods of treatment for the controlled release of a therapeutic substance to a treatment region are disclosed herein. In some embodiments, block copolymer-based release platforms (modified or unmodified) can be used to deliver a therapeutic substance to an inflamed site in, for example, the coronary... Agent: Blakely Sokoloff Taylor & Zafman

20080095848 - Pharmaceutical composition for topical use in form of xerogels or films and methods for production: The present invention relates to dry delivery system comprising a xerogel or film with applied active ingredients for topical active ingredient delivery or other purposes. Said delivery system are obtainable by a method according to the invention. The present invention also provides for methods for achieving defined localization of stable... Agent: Edwards Angell Palmer & Dodge LLP

20080095849 - Peptide sustained release compositions and uses thereof: Sustained delivery compositions that modulate the release of incorporated prophylactic, therapeutic, and/or diagnostic agents, and methods of preparation and use thereof, are disclosed. In particular embodiments, the compositions include a polymeric matrix; a prophylactic, therapeutic, and/or diagnostic agent dispersed and/or dissolved within the polymeric matrix; and a carbohydrate component that... Agent: Foley & Lardner LLP

20080095852 - Layered nanoparticles: The invention provides a process for forming a layered nanoparticle, comprising providing a suspension comprising a core particle in a first liquid, adding a second liquid to the suspension, and adding a reagent, or a precursor for the reagent, to the suspension. The second liquid is immiscible with the first... Agent: Foley And Lardner LLP Suite 500

20080095851 - Nanoparticulate fibrate formulations: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20080095850 - Process for granulating particles: The invention encompasses a process for granulating particles that produces homogeneous, free flowing, attrition resistant, uniform sized granules. When utilized with active pharmaceutical ingredients, such granules can be further processed into controlled released or taste-masked pharmaceutical formulations. Particularly, the process can be utilized to make an oral granule formulation of... Agent: Merck And Co., Inc

20080095854 - Dna dosage forms: The present invention relates to DNA formulations suitable for ballistic delivery into the skin of the human body. In particular the present invention provides DNA formulations suitable for ballistic administration of DNA vaccines into the skin. The present invention provides a novel DNA pharmaceutical agent dosage form, having a dense... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080095853 - Modified release for proton pump inhibitors: An oral solid pharmaceutical dosage form comprising an acid sensitive proton pump inhibitor (PPI) as single active drug, releasing the PPI in two separate pulses, one immediate and one delayed. The PPI is formulated into a core material in the form of pellets, which are coated i.a. with a combination... Agent: White & Case LLP Patent Department

20080095855 - Taste masking granules: Pellets of granulated particles comprising at least one pharmaceutically active compound, which pellets are characterised in that a bad taste of a pharmaceutically active compound when taken by patients is reduced or eliminated, said pellets comprise a pharmaceutically active compound and further comprise an organic carboxylic acid and/or a surfactant... Agent: Sandoz Inc

20080095856 - Encapsulated nanoparticles for drug delivery: Compositions and methods are provided for preparing nanosized biologically active agents, including agents formulated for target specific drug delivery. The nanosized agents are prepared with supercritical carbon dioxide as an antisolvent, providing nanoparticles whose size, shape, and surroundings are well-controlled. The nanoparticles are made of small molecules, e.g. drugs, anti-oxidants,... Agent: Bozicevic, Field & Francis LLP

20080095857 - Carrier system in the form of protein-based nanoparticles for the cell-specific enrichment of pharmaceutically active substances: A carrier system in the form of protein-based nanoparticles for the cell-specific, intracellular enrichment of at least one pharmacologically active substance. The system has structures that are coupled by reactive groups. The structures enable a cell-specific attachment and cellular absorption of the nanoparticles.... Agent: D. Peter Hochberg Co. L.p.a.

20080095858 - Screening of a novel hepatic syndrome and its uses: The invention concerns methods of screening for a hepatic syndrome occurring in the young adult and associating cholesterol biliary microlithiasis, intrahepatic cholestasis and several mutations of the MDR3 gene. The invention is also directed to methods for the treatment of said syndrome. The hepatic syndrome screening methods comprise detecting, from... Agent: Morgan Lewis & Bockius LLP

20080095859 - Formulations and treatments for well-being: A formulation for well-being in humans including: extracts from the herbal varieties, Polygonum multiflorum, Panax quinquefolium, Gingko biloba, and Equisetum arvense; beta sitosterol methyl sulfonyl methane; soy isoflavones; levo-arginine; inositol; niacin; pantothenic acid or salts thereof; alpha-tocopherol; biotin; pyridoxine hydrochloride zinc (or amino acid chelate thereof); and colostrum.... Agent: Abelman, Frayne & Schwab

20080095860 - Extracellular matrix to treat malignancy: The invention is articles, compositions and methods for inhibiting growth of an abnormally proliferating cell in a mammal; methods include inhibiting growth of abnormally proliferating cells after tumor resection, and methods of recruiting stem cells to a site of malignancy; articles include sheets of extracellular matrix, and compositions include liquid... Agent: Leigh Hunt Firestone

20080095861 - Antimicrobial and sporicidal composition: Germicidal compositions with enhanced activity towards killing microbiological spores and vetgetative cells comprising certain quaternary ammonium compounds (QACs), phenolic compounds, monohydric alcohols, hydrogen peroxide, iodine, triclocarban, triclosan or combinations thereof with one or more spore coat opening agents. The invention also provides for the application of the germicidal compositions to... Agent: Thorpe North & Western, LLP.

20080095862 - Biocide: A two part biocide composition containing metal ions and bromine donor for killing microorganisms in a body of water and a method of killing microorganisms in a body of water by placing both metal ions and a bromine in the body of water to allow use of lower concentrations of... Agent: Carl L. Johnson Jacobson And Johnson

20080095863 - 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions: 2-Pyrrolidone derivatives are provided as preservatives for topical formulations, particularly for ophthalmic, otic, and nasal formulations. N-octyl-2-pyrrolidone, without any other preservative or preservative aid in an isotonic pH 7.5 formulation, provided sufficient preservation to comply with the European Pharmacopoeia 5.0 standards in addition to the United States Pharmacopoeia 24 standards... Agent: Alcon

20080095864 - Methods for the preparation of concentrated aqueous bromine solutions and high activity bromine-containing solids: The invention includes convenient methods of preparing: (1) highly concentrated liquid bromine-containing biocidal solutions, (2) highly concentrated mixed halogen liquid bromine and chlorine-containing biocidal solutions, and (3) high-activity bromine-containing biocidal solids, all having excellent physical and chemical stability. One method yields solutions that have concentrations of bromine in excess of... Agent: Audrey A. Millemann Weintraub Genshlea Chediak

20080095865 - Composition and method for increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance: A dietary supplement comprising Creatinol O-Phosphate and Alpha Lipoic Acid, wherein the dietary supplement optionally comprises a timed-release or controlled-release delivery system. The timed-release or controlled-release delivery system may include one of quick release, slow release and controlled release delivery system. By way of oral administration, the present invention provides... Agent: Torys LLP

20080095867 - Hydroxycitric acid compositions from garcinia cambogia and hibiscus sp., methods of making, and therapeutic uses of same: Herbal compositions that comprise one or more of extracts of hydroxycitric acid, (−) HCA and (+) HCA, from Garcinia cambogia and Hibiscus sabdariffa, and anthocyanins from Hibiscus sabdariffa; all constituent extracts at independently controlled concentrations which optionally include second therapeutic agents and pharmaceutically acceptable additives. Processes for the preparation of... Agent: Greenberg Traurig LLP (la)

20080095866 - Topical compositions containing phosphorylated polyphenols: The present invention provides topical compositions containing phosphorylated polyphenols in combination with a topically acceptable carrier. The compositions of the invention provide a means for delayed delivery of the polyphenol to keratinous tissues, such as skin, hair and nails, with enzymes of the keratinous tissue dephosphorylating the polyphenol, and returning... Agent: The Estee Lauder Cos, Inc

20080095868 - Use of fermented wheat-germ in the feeding and veterinary practice: This invention relates to new uses of fermented wheat-germ extract namely for purposes of animal feeding and veterinary therapy. The subject matters of this invention are also the fodders, nutriments, premixes and veterinary preparations containing fermented wheat-germ extract.... Agent: Birch Stewart Kolasch & Birch

20080095869 - Anticancer treatment: A method of inhibiting tNOX in a living entity which includes administering to the entity, wherein the entity has cancer cells that express tNOX, a therapeutically active amount of a combination of botanicals selected from the groups consisting of cruciferous vegetables and Capsicum plants.... Agent: Nath & Associates

20080095870 - Composition of medicine, health-care product and cosmetics for treating chloasma: This invention relates to the composition of medicine, also a health-care product, cosmetics for treating chloasma and the method of the composition preparation and application. The composition contains active extracts of atractylodes lancea, semen coicis, and phellodendron amurense rupr, which are ruptured by solvent in weight ratio of 1:0.5-5:0.5-5.... Agent: Squire, Sanders & Dempsey L.L.P.

20080095871 - Bacterial product from marive origin, useful for preventing the macro biofouling caused by macroalgae and marine invertebrates: Extra-cellular product anti-biofouling against marine invertebrates which are common to the biofouling, which contains an extract of the supernatant of an Alteromonas sp. Culture. Anti-biofouling composition, comprising said extra-cellular product and a biopolymer. The use of said extra-cellular product for preparing a composition useful for inhibiting the marine micro- and... Agent: Hasse & Nesbitt LLC

20080095872 - Clostridial toxin derivatives and methods for treating pain: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting... Agent: Allergan, Inc.

20080089836 - Functional associative coatings for nanoparticles: Described herein are nanoparticles that are coated with a bilayer of molecules formed from surface binding molecules and amphiphatic molecules. The bilayer coating self assembles on the nanoparticles from readily available materials/molecules. The modular design of the bilayer coated nanoparticles provides a means for readily and efficiently optimizing the properties... Agent: Wilson Sonsini Goodrich & Rosati

20080089839 - Preparation of stable high concentration coloidal metal particulate system: Gold suspensions with high concentrations of gold, and silver suspensions with high concentrations of silver, are provided. Gold or silver nanoparticles are put into suspension, where the metal nanoparticles are paired with silica. Biocompatible suspensions are one application. Noble metal particles, attached to the surface of silica particles, form a... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080089848 - Intrathecal injection of microbubbles: A method of delivering a therapeutic drug to a brain of a patient, involving intrathecally administering a microbubble composite containing a therapeutic agent, allowing the composite to rise into the cranium, and applying ultrasound to the cranium to explode the microbubbles.... Agent: Philip S. Johnson Johnson & Johnson

20080089850 - Compositions comprising combinations of sensates: Compositions comprising a first sensate, a second sensate, and a cationic polymeric compound are described, as well as methods for using such compositions in oral care and personal care applications.... Agent: Colgate-palmolive Company

20080089867 - Method of increasing retention, survival and proliferation of transplanted cells in vivo: A method of increasing retention, survival and proliferation of transplanted cells in diseased or damaged tissue types or organ by providing transplanted cells with autologously-derived platelet cells and forming a autologously-derived platelet gel prior or during administration to the tissue type or organ through a delivery device and immobilizing the... Agent: Fox Rothschild, LLP

20080089866 - Novel bone mineralization protein expression systems, and methods of studying their intracellular signaling pathways: The present invention is directed to methods of switching a differentiation of a cell from a non-osteogenic lineage into an osteogenic lineage. The present invention is also directed to methods of generating a model system for assessing the intracellular signaling pathways of bone growth factors.... Agent: Fox Rothschild, LLP

20080089878 - Compositions and methods for treating conditions related to ephrin signaling with cupredoxins: The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080089838 - Chimeric, human and humanized anti-csap monoclonal antibodies: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.... Agent: Faegre & Benson LLP Patent Docketing

20080089837 - Targeted binding agents directed to pdgfr-alpha and uses thereof: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080089840 - Bioswellable sutures: Bioswellable sutures are provided in the form of absorbable, compliant monofilaments of an amphiphilic copolyester, an absorbable multifilament braid, a non-absorbable monofilament with swellable outer layer, a non-absorbable multifilament braid with an absorbable monofilament core of an amphiphilic copolymer, and a non-absorbable, multifilament braid molecularly integrated with an outer sheath... Agent: Leigh P. Gregory

20080089841 - Continuous vessel-selective spin labeling: The invention relates to a method for the MRT representation of a blood vessel (A) and/or of the territory supplied by the blood vessel (A) by labeling the blood, which is guided by this blood vessel (A), by means of continuous arterial spin labeling (CASL), in a specified labeling plane... Agent: Diederiks & Whitelaw, PLC

20080089842 - Flexibly labeling peptides: A solid phase peptide synthesis method for synthesizing a peptidyl contrast agent is disclosed. In one example, the method includes synthesizing an amino-chelator loaded resin, coupling of the amino-chelator loaded resin to the C-terminus and/or backbone of a peptide, cleaving the amino-chelator-peptide from a resin, and chelating a lanthanide metal... Agent: Mcdonald Hopkins LLC Suite 2100

20080089844 - Kappam-conopeptides as organ protectants: The invention relates to κM conopeptides and their use as organ protecting agents, i.e., organ protectants. These conotoxins can be used for arresting, protecting or preserving an organ, such as a circulatory organ, a respiratory organ, a urinary organ, a digestive organ, a reproductive organ, an endocrine organ or a... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080089845 - Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo: Described herein is a method for determining an effective dose of a composition for inhibiting fatty acid amide hydrolase activity in vivo, by first administering to a subject a dose of a test composition, and subsequently assessing if the level of a fatty acid amide in the subject increases. Also... Agent: Organon Usa, Inc. Patent Department

20080089843 - Use of biomarkers of inflammation as indicators of drug efficacy: The present invention provides methods for assessing the anti-inflammatory efficacy of drug substances using one or more biomarkers of inflammation. Kits for performing the disclosed methods are also provided.... Agent: Reddy US Therapeutics, Inc

20080089846 - Systems and methods for assessing pulmonary gas transfer using hyperpolarized 129xe mri: Methods and systems for assessing pulmonary gas exchange and/or alveolar-capillary barrier status include obtaining at least one MRI image and/or image data of 129Xe dissolved in the red blood cells (RBC) in the gas exchange regions of the lungs of a patient. The image is sufficiently sensitive to allow a... Agent: Myers Bigel Sibley & Sajovec

20080089847 - Isotopically labeled polyfluorinated compound useful as an imaging tracer: where R1 is —C(O)OR2, —C(O)N(R3)2, C—N(R3)2, —C(NR3)R2, C-QR3, -QR3, —N+(R3)3, X, C1-C30 alkyl, C1-C30 haloalkyl, C1-C30 alkoxyl, or C1-C30 perhaloalkyl; R2 is MZ+, H, C1-C12 alkyl, C1-C12 alkyl, C1-C12 perhalo alkyl, C6-C30 aryl, C6-C30 perhaloaryl, and a substituted form thereof where one or more protons or halogens is replaced with... Agent: Gifford, Krass, Sprinkle, Anderson & Citkowski, P.C.

20080089849 - Powders for inhalation: The invention therefore relates to protein-containing powders, wherein the proportion of phenylalanine is at least 30% (w/w), or at least 40% (w/w). It has been shown that phenylalanine-containing powders, particularly after spray drying, are very suitable in terms of their aerodynamic characteristics and protein stabilisation for preparing powders or protein... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080089851 - Brown algae cell lyophilisate, method for the obtention thereof: This invention is related to a freeze-dried product of cells of brown algae, the process for obtaining thereof, a cosmetic composition containing thereof, a food complement containing thereof, and the use thereof.... Agent: Birch Stewart Kolasch & Birch

20080089852 - Additive for uv-sunscreen preparations: The invention relates to the use of polymeric particles for boosting the UV absorption of an UV filter in an UV-sunscreen composition, wherein the polymeric particles comprise at least one polymeric particle comprising at least one chromophore having an UV absorption maximum at λmax≧275 nm covalently bound thereto.... Agent: Nixon & Vanderhye, PC

20080089853 - Amphoteric ethyl methacrylate copolymers and use thereof: The present invention relates to amphoteric copolymers which comprise ethyl methacrylate, if appropriate a N-vinyllactam compound, at least one monoethylenically unsaturated carboxylic acid and at least one compound with α,β-ethylenically unsaturated double bond and at least one cationogenic and/or cationic group in copolymerized form, to cosmetic and pharmaceutical compositions which... Agent: Connolly Bove Lodge & Hutz, LLP

20080089854 - Skin care compositions: Provided are compositions which are suitable for topical application to human skin for cleansing and anti-microbial properties. In one preferred embodiment, the compositions include a glyceryl monoazelate ester. In another embodiment, the compositions include a glyceryl monoazelate monolaurate ester. It is postulated that bacteria on the skin cleave the ester... Agent: Christopher J. Whewell Western Patent Group

20080089855 - Non-fluid hair treatment product comprising hair fixative absorbed on waxy carrier: The present invention relates to non-fluid hair treatment products comprising a fluid composition which is absorbed on a waxy carrier, wherein the fluid composition contains at least one hair fixing agent, e.g. a hair fixing polymer. The products can be made by pulverizing a fluid hair styling composition on a... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080089856 - Pulverized hair care treatment: The present invention relates to pulverized, non-fluid hair conditioning products comprising a fluid hair conditioning composition which is absorbed on a solid carrier, wherein the fluid hair conditioning composition contains at least one hair care agent, selected from the group consisting of hair conditioning surfactants, hair conditioning polymers, hair conditioning... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080089857 - Fly gel bait: The invention relates to baits for controlling flies (fly gels) comprising a) one or more neonicotinoids, b) one or more gelling agents, c) one or more attractants, and having a gel point between having a Brookfield yield value between 150 and 1000 and a Brookfield viscosity between 40,000 and 150,000... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080089858 - Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism: e

20080089859 - Administration of sleep restorative agents: The present invention provides methods and compositions for increasing the efficacy of a therapeutic agent administered to a subject. A steep restorative agent is co-administered to the subject along with the therapeutic agent, whereby the efficacy of the therapeutic agent is increased.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20080089860 - Therapeutic compositions and methods useful in treating cancer: The invention encompasses therapeutic compositions containing a pentavalent antimonial composition. The pentavalent antimonial can be sodium stibogluconate and pentamidine and biological equivalents of said compounds. The therapeutic composition of this embodiment contains an effective amount of pentavalent antimonial that can be used in treating diseases. The types of diseases that... Agent: Morgan Lewis & Bockius LLP

20080089861 - Combination therapy for treatment of demyelinating conditions: The invention provides compositions and methods for treating autoimmune diseases such as multiple sclerosis. The compositions include a combination of an NMDA Receptor antagonist, such as memantine or rimantadine, and a fumarate agent, such as dimethyl fumarate.... Agent: Adamas Pharmaceuticals, Inc.

20080089862 - Protease inhibitors and method of screening thereof: The present invention provides novel recombinant protein and peptide inhibitors of NS3 serine protease of the hepatitis C virus (HCV). The invention discloses analogs, fragments and derivatives of the identified inhibitors, nucleic acids encoding same, and methods of use thereof for the treatment of HCV infection. The invention further provides... Agent: Winston & Strawn LLP Patent Department

20080089864 - Adenoviruses mutated in the va genes for cancer treatment: This invention refers to the use of an adenovirus for cancer treatment, being this adenovirus defective in its virus-associated (VA) RNAs. Said adenovirus has a mutation in the VAI or VAII gene sequence or both. This adenovirus may also have mutations in the sequences controlling expression of the VA RNAs.... Agent: Fish & Richardson P.C.

20080089863 - Non-integrative and non-replicative lentivirus , preparation and uses thereof: The invention concerns a non-integrative and non-replicative recombinant lentivirus as well as its uses, in particular for preparing a composition for transferring genes in vitro, ex vivo or in vivo. The invention is useful for transferring genes in any mammal organism, for example in liver, muscle, pancreas or central nervous... Agent: Nixon & Vanderhye, PC

20080089874 - Directed differentiation and maturation of stem cell-derived cardiomyocytes: This invention provides an isolated electrophysiologically immature cell or its derivative that has been modified to provide a mature electrophysiological phenotype and populations of these cells. Compositions containing these cells and populations of cells are also provided by this invention. These cells and compositions have therapeutic and diagnostic uses. Non-limiting... Agent: Foley & Lardner LLP

20080089873 - Method for regenerating hair follicles by suppressing a gene with hair follicle formation-inhibiting ability or by activating a gene with hair follicle formation-inducing ability: It is intended to provide a method of regenerating follicles which comprises inhibiting the expression of one or more genes capable of inhibiting follicle formation that are selected from the group consisting of S100a6, Ctgf, Gsto1, Gas6, Klf2, Thbs1 and Thbd, or promoting the expression of one or more genes... Agent: Snider & Associates

20080089865 - Materials and methods for regulating process formation in cell culture: The subject invention pertains to materials and methods for inhibiting process formation and extension by cells in culture. The subject invention further includes cultures of process-forming cells wherein formation and extension of processes have been inhibited. In another aspect, the subject invention concerns methods of transplantation using process-forming cells that... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080089871 - Compositions and methods for the treatment and repair of defects or lesions in articular cartilage using synovial-derived tissue or cells: Compositions and methods are provided for treatment of cartilage defects in animals and humans. The compositions of the invention include synovial tissue, synovial cells and matrices containing synovial (or cambium) tissue or cells for use in filling a cartilage defect. The matrix and synovial tissue or cell preparations may also... Agent: Ropes & Gray LLP

20080089870 - Cultured melanocytes on bioploymer membranes for treatment of hyper and hypopigmentation disorders: The present invention relates to a graft wherein cultured autologous melanocytes are delivered using a biopolymer. The present invention describes the composition, method of preparation and its properties relating to safety and efficacy. The graft of the present invention has a potential use in treating hyper- and hypopigmentation disorders.... Agent: Foley And Lardner LLP Suite 500

20080089872 - Method for purifying pluri-differentiated mesenchymal progenitor cells: There is provided an isolated pluri-differentiated human mesenchymal progenitor cells (MPCs), a method for isolating and purifying human mesenchymal progenitor cells from Dexter-type cultures, and characterization of and uses, particularly therapeutic uses for such cells. Specifically, there is provided isolated MPCs which can be used for diagnostic purposes, to enhance... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080089869 - Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer: Disclosed herein are modified proaerolysin (PA) peptide. In some examples, the proteins include a prostate-specific protease cleavage site and can further include a prostate-tissue-specific binding domain which functionally replaces the native PA binding domain. In other examples, the proteins include a furin cleavage site and a prostate tissue-specific binding domain... Agent: Klarquist Sparkman, LLP

20080089868 - Retinal stem cell compositions and methods for preparing and using same: Provided are cell compositions including non-retinal cell types that have been reprogrammed to form retinal stem cells, and methods for producing and using same. Such reprogrammed cells can be used to replace one or more retinal cell types that have been lost due to damage and/or disease and are thus... Agent: Heslin Rothenberg Farley & Mesiti PC

20080089875 - Methods and compositions for the treatment of cancer: A method of treating cancer comprises: (a) providing allogenic or autologous white blood cells from a suitable donor; and then (b) administering the white blood cells to the subject in an amount effective to treat the cancer. Preferably the white blood cells comprise innate immune cells. Preferably the white blood... Agent: Myers Bigel Sibley & Sajovec

20080089876 - Composition containing statins and omega-3 fatty acids: A combination is described comprising at least one omega-3 fatty acid, optionally esterified or salified, at least one statin, Coenzyme Q10, resveratrol, at least one policosanol, pantethine, selenium, and zinc. This combination is endowed with a synergistic effect and is useful in the treatment of disease forms due to insulin... Agent: Nixon & Vanderhye, PC

20080089877 - Super absorption coenzyme q10: An improved soft gelatin formulation and process methodology that increases single Coenzyme Q10 molecules presented to the absorption channels of the small intestines by providing medium chain triglycerides, Vitamin E and natural beta carotene to Coenzyme Q10 in a soft gel capsule to increase the absorption thereof.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080089879 - Phytases and methods of making and using them: A purified, isolated, synthetic or recombinant phytase enzyme (e.g., SEQ ID NO:2) derived from Escherichia coli B. The enzyme has a molecular weight of about 47.1 kilodaltons and has phytase activity (SEQ ID NO:2). The enzyme can be produced from native or recombinant host cells and can be used to... Agent: Verenium C/o Mofo S.d.

20080089880 - Biological bioadhesive compositions and methods of preparation and use: The present invention relates generally to the preparation and use of biological tissue adhesives which rely on combining fibrinogen and thrombin. More particularly, the present invention relates to a method of preparing a fibrin sealant whereby said sealant is formed by reconstituting the fibrinogen or the thrombin component in the... Agent: O'keefe, Egan, Peterman & Enders LLP

20080089883 - Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an... Agent: Keown & Zucchero, LLP

20080089881 - Treatment and diagnostics of inflammatory diseases: A method of determining whether a subject is suffering from or at risk for developing inflammatory diseases by determining the level of HM74 and/or HM74A in tissue damage. Also disclosed are a method of identifying a compound for treating inflammatory diseases, a method of treating inflammatory diseases, and a pharmaceutical... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080089885 - Anti-cd20 antibodies and methods of use: Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies capable of binding to a human CD20 antigen located on the surface of a human CD20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (CDC) that is... Agent: Alston & Bird LLP

20080089884 - Compositions and methods for the modulation of detrusor activity: The invention relates generally to methods for treating and/or preventing bladder disorders. In certain embodiments the invention comprises methods for the treatment and/or prevention of a bladder disorder comprising administering an effective amount of a therapeutic agent that decreases the expression, release or biological activity of macrophage migration inhibition factor... Agent: Mccarter & English LLP Cityplace I

20080089886 - Gene differentially expressed in breast and bladder cancer and encoded polypeptides: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080089882 - Novel polypeptide useful for cancer diagnosis and treatment: The present invention provides a method capable of effectively detecting cancer by finding a novel cancer marker. The present invention also provides a pharmaceutical composition for preventing or treating cancer. The present invention relates to a method for detecting cancer by detecting the expression of a U7 polypeptide in a... Agent: Birch Stewart Kolasch & Birch

20080089887 - Members of the fc receptor homolog gene family (fcrh1-3,6) related reagents and uses thereof: The invention relates to members of the Fc receptor homolog (FcRH) subfamily, as well as fragments and variants thereof. Each FcRH is a Type I transmembrane receptor, preferably, comprises an extracellular region, a transmembrane region, and a cytoplasmic region. The cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory... Agent: Fish & Richardson P.C.

20080089888 - Human sarcoma-associated antigens: The invention relates to sarcoma-associated antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof associated with sarcoma in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the... Agent: Wolf Greenfield & Sacks, P.C.

20080089891 - Cancerous disease modifying antibodies: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can... Agent: Mchale & Slavin, P.A.

20080089890 - Methods of polypeptide production: The present invention relates to methods and compositions for adenovirus mediated production of a polypeptide of interest in replication non-permissive cells. The invention also relates to compositions resulting from the methods and uses according to the invention.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080089889 - Novel bone metastasis marker peptide and method of diagnosing bone metastasis by using the same: It is intended to provide: a peptide which shows an increase in the expression amount in the serum of a cancer patient with the passage of time before the onset of bone metastasis and after the onset of bone metastasis, is adsorbed by a weak cation exchanger at pH 6,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080089892 - Fc region variants: The present invention provides polypeptide Fc region variants and oligonucleotides encoding Fc region variants. Specifically, the present invention provides compositions comprising novel Fc region variants, methods for identifying useful Fc region variants, and methods for employing Fc region variants for treating disease.... Agent: Eli Lilly & Company

20080089893 - Therapeutic application of chimeric and radiolabelled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20... Agent: Sidley Austin LLP Attn: Dc Patent Docketing

20080089894 - Transplant tolerance by costimulation blockade and t-cell activation-induced apoptosis: The invention relates to methods of inducing tolerance and preventing transplant rejection by blocking costimulatory signals and using immunosuppressive agents, preferably rapamycin, to prevent late rejection episodes, yet not block tolerance inducing T-cell specific depletion; compositions and kits for use in such methods are also provided herein.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080089895 - Use of t-cell immune response cdna 7 (tirc7) in angiogenic and anti-angiogenic therapy: A novel use of T-cell immune response cDNA 7 (TIRC7) in angiogenic and anti-vided angiogenic therapy is described. Provided are agents such as anti-TIRC7 antibodies and methods of treatment which through modulating the activity of TIRC7 can be used for enhancing or suppressing angiogenesis and/or neovascularization, an important feature in... Agent: John P. White Cooper & Dunham LLP

20080089896 - Bivalent smac mimetics and the uses thereof: The invention relates to bivalent mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.... Agent: Medlen & Carroll, LLP

20080089897 - Actriib fusion polypeptides and uses therefor: Methods and compositions for inhibiting growth and differentiation factor-8 (GDF-8) activity in vitro and in vivo are provided. The methods and composition can be used for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or glucose homeostasis.... Agent: Wyeth/finnegan Henderson, LLP

20080089898 - Immunotoxins directed against cd33 related surface antigens: The present invention provides novel immunotoxins and methods of treating neoplastic diseases. These immunotoxins are comprised of a conjugation of an antigen binding region exhibiting binding specificity for the CD33 protein and a cell growth modulator. The immunotoxins of the present invention specifically and selectively kill tumor cells that are... Agent: Fulbright & Jaworski, L.L.P.

20080089900 - Identification of self and non-self antigens implicated in autoimmune disease: The present invention provides isolated peptides relating to the autoimmune diseases pemphigus vulgaris and multiple sclerosis. The peptides relating to pemphigus vulgaris are self epitopes and those relating to multiple sclerosis are foreign antigens derived from human pathogens which are implicated in the aetiology and remissions of the disease. Pharmaceutical... Agent: Ropes & Gray LLP

20080089899 - Streptococcus pneumoniae proteins and nucleic: Protein antigens from Streptococcus pneumoniae are disclosed, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.... Agent: Hunton & Williams LLP Intellectual Property Department

20080089902 - Fusion proteins comprising hiv-1 tat and/or nef proteins: The invention provides (a) an HIV Tat protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Nef protein or derivative thereof; or (b) an HIV Nef protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Tat protein or... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080089901 - Hivcon: an hiv immunogen and uses thereof: The present invention provides artificial fusion proteins (AFPs) designed to elicit an anti-HIV immune response, as well as nucleic acid molecules and expression vectors encoding those proteins. The AFPs of the invention may comprise domains from various HIV proteins, such as Gag, Pol, Vif, and Env proteins, which are partial... Agent: Frommer Lawrence & Haug

20080089903 - Cd4+t-lymphocyte-specific hepatitis c virus epitopes: The invention relates to hepatitis C virus epitopes which are CD4+ T-lymphocyte specific, and to vaccines containing these epitopes.... Agent: Foley And Lardner LLP Suite 500

20080089904 - Clostridium toxin, and process for the preparation of immunogenic composition: The present invention relates to the field of bacterial toxic proteins, in particular toxins from Clostridium or other pathogenic organisms using, for example, promoter nucleic acids to control expression of polypeptides such as bacterial toxins.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080089906 - Use of substances to protect fgf-2 or fgf-beta growth factor: e

20080089905 - Compounds for stimulating stem cell proliferation including afa-omega (etoh): A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of substances selected from blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3, Spirulina, AFA or effective combinations and derivatives of these.... Agent: Christopher Paradies, Ph.d.

20080089907 - Modified vaccinia ankara virus variant: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a... Agent: The Firm Of Hueschen And Sage

20080089909 - Hiv-1 clade a consensus sequences, antigens, and transgenes: The present invention relates to consensus nucleotide and protein sequences for HIV-1 Clade A antigens, and to nucleotide and protein sequences for Clade A antigens from circulating HIV-1 field isolates wherein the antigen sequences are closely related to the these consensus sequences. In a preferred embodiment, the present invention relates... Agent: Frommer Lawrence & Haug

20080089908 - Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations... Agent: Novartis Vaccines And Diagnostics Inc.

20080089910 - Attenuated herpes simplex virus type-2, vectors thereof and immunogenic compositions thereof: The present invention broadly relates to the attenuation of herpes simplex virus type 2 (HSV-2). More particularly, the invention relates to the identification of mutations in the HSV-2 UL24 gene which attenuate the pathogenicity of HSV vectors in mammals and immunogenic compositions thereof.... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20080089911 - Immunological combination compositions and methods: Immununological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader... Agent: Robert Yoshida Sanofi Pasteur Inc.

20080089912 - Intrathecal injection of microbubbles containing a thrombolytic agent: A method of delivering a therapeutic drug to a brain of a patient, involving intrathecally administering a microbubble composite containing a therapeutic agent, allowing the composite to rise into the cranium, and applying ultrasound to the cranium to explode the microbubbles.... Agent: Philip S. Johnson Johnson & Johnson

20080089916 - Botanical butter stick lip balm: A stick lip balm with efficacious amounts of natural moisturizer and organoleptic/sensory attributes of lip feel associated with moisturizers and emollients is provided. The lip balm of the invention comprises at least 90% botanically derived materials and can be formed into a stick sufficiently robust to substantially retain the stick... Agent: Wyeth Patent Law Group

20080089913 - Capsule whose envelope is separately imperceptible during the topical use thereof: A capsule for cosmetic and/or dermatological ingredients and processes for the production thereof. The capsule comprises an envelope which is solid, semisolid and/or dimensionally stable and comprises one or more substances which are selected from waxes, emulsifiers, and natural and synthetic polymers. The capsule may also comprise a filling.... Agent: Greenblum & Bernstein, P.L.C

20080089917 - Cosmetic composition: c

20080089914 - Low ph pharmacologically active products and methods for the production thereof: There is provided a new technology that will allow the formulation of pharmaceutically active organic acid products at relatively high pH during storage. This affords the advantages of avoiding formulation with the acid form of the product, yet when the product is used, the pH will be reduced via a... Agent: Omri M. Behr

20080089915 - Use of a specific inhibitor of hedgehog/smoothened signaling on hyperpigmented skin to obtain decrease of pigmentation: Cyclopamine or a similarly specific inhibitor of Hedgehog/Smoothened (Hh/Smo) signaling can be used for obtaining decrease of pigmentation of hyperpigmented skin areas.... Agent: Vidas, Arrett & Steinkraus, P.A.

20080089920 - Apparatus for piezoelectric layer-wise pump and valve for use in local administration of biological response modifiers and therapeutic agents: A method and apparatus for local infusion of a variety of biological response modifiers (BRMs) and chemotherapeutic agents including tumor necrosis factors (TNF) is described. In one embodiment, the device contains a synthetic pouch compartmentalized into three or more chambers, and an electronic apparatus controlling and modulating the delivery of... Agent: Myers Dawes Andras & Sherman, LLP

20080089921 - Apparatus for piezoelectric layer-wise pump and valve for use in local administration of biological response modifiers and therapeutic agents: A method and apparatus for local infusion of a variety of biological response modifiers (BRMs) and chemotherapeutic agents including tumor necrosis factors (TNF) is described. In one embodiment, the device contains a synthetic pouch compartmentalized into three or more chambers, and an electronic apparatus controlling and modulating the delivery of... Agent: Myers Dawes Andras & Sherman, LLP

20080089919 - Immobilized biologically active entities having a high degree of biological activity: The present invention relates to immobilized biologically active entities having heparin cofactor II binding activity.... Agent: Gore Enterprise Holdings, Inc.

20080089918 - Viscoelastic solutions containing sodium hyaluronate and hydroxypropyl methyl cellulose, preparation and uses: from 1 to 2% by weight of at least one sodium hyaluronate having an average molecular weight of between 1.106 g/mol and 3.5.106 g/mol; and from 0.2 to 1% by weight of at least one hydroxypropyl methyl cellulose having an average molecular weight of between 10,000 g/mol and 110,000 g/mol;... Agent: Cohen, Pontani, Lieberman & Pavane

20080089922 - Laminin-modified conduit for nerve regeneration and methods of manufacturing the conduit and regenerating nerves using the conduit: A laminin-modified polymeric hollow conduit is provided for promoting nerve regeneration across the gap between severed ends of a nerve. The conduit is manufactured by a method involving gas plasma treatment. Utilizing the laminin-modified conduit, functional recovery has been achieved in mammals with a severed spinal cord.... Agent: Panitch Schwarze Belisario & Nadel LLP

20080089923 - Biodegradable ocular implants and methods for treating ocular conditions: Biodegradable ocular implants are described. The ocular implants include a bioactive agent that can be released within the eye to treat an ocular condition or indication. The implants can be used for the administration of a bioactive agent over prolonged periods of time. In some aspects the implants are formed... Agent: Kagan Binder, PLLC

20080089924 - Multimeric oleamide derivative having connexin-26 inhibiting potency and use thereof in cancer therapy, etc.: where n denotes an integer of 3, 5, or 8. The novel oleamide derivatives of the present invention can be used not only as research reagents, but also in a wide industrial field because they exhibit useful bioactivities such as cancer metastasis/growth inhibition. Thus they have various applications, such as... Agent: Kirk Hahn

20080089925 - Drug for external use and adhesive patch: An external preparation characterized by containing a pharmacologically active component such as an anti-inflammatory drug and an edetic acid salt, and containing substantially no water.... Agent: Nath & Associates

20080089926 - External patches containing etofenamate: The present invention provides to patches having excellent skin-permeability and therapeutic effect by the drug with lower irritation. In an external patch in which an adhesive layer containing an adhesive base and a drug are laminated with a backing, the external patch wherein the adhesive base contains 5-50% by weight... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080089932 - Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome: An amphoteric liposome composed of a mixture of lipids, said mixture comprising a cationic amphiphile, an anionic amphiphile and optionally one or more neutral amphiphiles, at least one of said cationic and anionic amphiphiles being chargeable and the respective amounts of said cationic and anionic amphiphiles being selected such there... Agent: Ivor R. Elrifi, Esq. Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20080089931 - Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders: The present invention relates to methods and compositions designed for treatment, management, or prevention of a hyperproliferative cell disease, particular cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing low molecular weight protein tyrosine kinase (“LMW-PTP”) in particular using... Agent: Johnathan Klein-evans

20080089929 - Fusion proteins comprising hiv-1 tat and/or nef proteins: The invention provides (a) an HIV Tat protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Nef protein or derivative thereof; or (b) an HIV Nef protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Tat protein or... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080089930 - Keratin-based powders and hydrogel for pharmaceutical applications: A hydratable, highly absorbent keratin solid fiber or powder capable of absorbing a large weight excess of water may be produced by partially oxidizing hair keratin disulfide bonds to sulfonic acid residues and reacting the sulfonic acid residues with a cation. The neutralized suspension can be filtered, washed, and dried,... Agent: Vinson & Elkins, L.L.P.

20080089928 - Liposome drug carriers with ph-sensitivity: A liposome composition for delivering of a biologically active agent having at a least first rigid lipid and a second rigid lipid each having a head group and a hydrophobic tail; a polyethyleneglycol-linked lipid having a side chain matching at least a portion of the first or the second lipid;... Agent: Smith, Gambrell & Russell

20080089927 - Methods for coacervation induced liposomal encapsulation and formulations thereof: The present invention relates to methods of preparing liposomal formulations of active agents comprising varying the reaction parameters to form a coacervate which yields liposomal formulations of unusually high active agent (drug) to lipid ratios.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080089933 - Device and method for reducing calorie intake: Devices and methods for substantially reducing the caloric efficiency of the digestive tract by capturing food being digested in the stomach 10 and/or anywhere else in the gastrointestinal (GI) tract, absorbing or encapsulating the captured food into multiple capturing members and moving such multiple capturing members containing the ingestible encapsulated... Agent: Itzhak Katz

20080089934 - Process for making gel films: The present invention is directed to a process for making homogeneous, thermoreversible gel films comprising the steps of: (i) heating, hydrating, mixing, solubilizing, and, optionally, de-aerating a high solids, low moisture film forming composition in an apparatus providing sufficient shear, temperature and residence time to form a homogeneous molten composition,... Agent: Paul A. Fair, Patent Administration Fmc Corporation

20080089935 - Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it: This invention relates to solid and stable dispersions of a hydrosoluble derivative of vinca alkaloids in at least one polyethyleneglycol with a molecular mass between 800 and 30 000.... Agent: Birch Stewart Kolasch & Birch

20080089936 - Prolonged release formulation of active principles having a ph-dependent solubility: The invention concerns a novel formulation for prolonged release of an active principle having a pH-dependent solubility. The inventive formulation comprises a matrix support based on hydrophilic polymer containing a specific dose of active principle, and further comprises one or more acidifying agents in the form of an acid salt... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080089937 - Controlled release drug compositions and preparation methods: A drug core composition is described for enhancing controlled delivery of pharmaceutical active agents with low solubility in water. The drug core composition contains at least a drug-layer and a push-layer. The drug-layer contains at least a pharmaceutical active agent with low solubility in water and a hydrophilic polymer carrier.... Agent: Beyer Weaver LLP

20080089938 - Compositions and methods for polynucleotide delivery: This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or... Agent: Novartis Vaccines And Diagnostics, Inc. Intellectual Property

20080089939 - Dermastick thickened ointment: Provided is a solid stick topical composition containing a corticosteroid. The solid stick also contains petrolatum, wax, propyleneglycol and emulsifier. The solid stick is contained in a protective covering so that during application it does not come in contact with the hand holding the stick.... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20080089940 - Superporous hydrogels for heavy-duty applications: The present invention features modified superporous hydrogels (SPHs) and methods for their formation. The SPHs of the present invention are prepared by careful selection of the hydrophobic/hydrophilic reactive ingredients and by harmonizing the foaming and polymerization reactions, which results in the formation of SPHs having a homogeneous structure and favorable... Agent: Robert Deberardine Abbott Laboratories

20080089944 - Method for precipitation of small medicament particles into use containers: Commercially feasible methods for lyophobic precipitation of liquid-dispersed or dissolved material (e.g., medicaments) are provided wherein a plurality of individual, open containers (22) each containing a quantity (84) of a solution or dispersion are treated within a common pressurizable chamber (12). In this process, desired near-supercritical or supercritical temperature and... Agent: Hovey Williams LLP

20080089941 - Fucoidan compositions and methods: Compositions and methods relating to partially hydrolyzed fucoidan for use in dietary supplements and skin-care products are described. Fucoidan from brown seaweeds is partially hydrolyzed and/or sulfonated and then mixed with other ingredients for use as a dietary supplement in beverage, capsule, or tablet form or for use as a... Agent: Alan J. Howarth

20080089943 - Use of adsorbent carbon microspheres to treat gastroesophogeal reflux disease: Disclosed herein is the use of adsorbent carbon microspheres for the treatment of gastroesophogeal reflux disease. The adsorbent carbon microspheres may be administered alone or in combination with a proton pump inhibitor.... Agent: Knobbe Martens Olson & Bear LLP

20080089942 - Use of adsorbent carbon microspheres to treat intestinal bacterial infections: Disclosed herein is the use of adsorbent carbon microspheres for the treatment of intestinal bacterial infections. The infections include infection with Escherichia coli, Shigella dysenteriae, Vibrio cholerae, and Clostridium difficile. The adsorbent carbon microspheres serve to adsorb or bind toxins produced by the bacteria.... Agent: Knobbe Martens Olson & Bear LLP

20080089945 - Methods and compositions for promoting normal cell growth and inhibiting cancer cell growth: The present invention provides novel compositions and methods for pharmaceutical or nutraceutical use in an animal, preferably in a human. In one aspect, compositions and methods are provided for promoting normal healthy cell growth and inhibiting cancer cell growth, and for treating or preventing cancer by restoring homestatic balance of... Agent: Wilson Sonsini Goodrich & Rosati

20080089946 - Synergistic phytoceutical compositions: Phytoceutical compositions for the prevention and treatment of circulatory disorders, feminine endocrine disorders, and dermal disorders. A specific combination of extracts of plants is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants... Agent: Baker & Mckenzie LLP

20080089947 - Calcium influx inhibitors in the treatment of ischemia: The present invention concerns the use of calcium influx inhibitors for treatment of organs and tissues to inhibit damage caused by ischemia/reperfusion events such as transplant, other surgeries, and trauma. It includes methods and apparatuses for achieving stasis in tissue, so as to preserve and/or protect them. In specific embodiments,... Agent: Fulbright & Jaworski L.L.P.

20080089948 - Method of use for lanthanum carbonate and lanthanum hydroxycarbonate: A method for treating hyperphosphatemia using lanthanum carbonate, including analytically determining the amount of an impurity in the lanthanum carbonate sample is provided. This X-ray diffraction method preferably uses the Rietveld refinement.... Agent: Darby & Darby P.C.

20080089949 - Method for treating cancer using oral arsenic trioxide: The invention provides a method for treating cancers that are dependent on cyclin D1 for proliferation, survival, metastasis and differentiation, involving administering effective amount of arsenic trioxide to an affected patient.... Agent: Cooper & Dunham, LLP

20080089951 - Method for inhibiting cancer using arsenic trioxide: It has been discovered that As2O3 suppresses tyrosine kinase receptors, in particular EGFR and IL-6R, by targeting RTKs to lysosomes and/or proteasome for degradation. This is the basis for the discovery that cancers dependent on RTKs for signaling, proliferation, survival, metastasis and differentiation can be treated with As2O3, preferably oral... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080089950 - Methods and compositions for modulating the immune system and uses thereof: The present invention provides methods of preventing, treating or ameliorating one or more symptoms of disorders in which modulation of a subject's immune system is beneficial utilizing a lymphoid tissue inducing agent and an immunomodulatory agent. In particular, the present invention provides methods of preventing, treating or ameliorating a proliferative... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080089952 - Compositions and methods for coating medical implants: Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.... Agent: Seed Intellectual Property Law Group PLLC

20080089953 - Self-preserved ophthalmic pharmaceutical compositions containing tobramycin: Self-preserved, multi-dose ophthalmic compositions containing tobramycin are described. The compositions do not contain a conventional antimicrobial preservative, such as benzalkonium chloride. Rather, the compositions are self-preserved as a result of the inherent antimicrobial activity of tobramycin. The compositions preferably also contain either boric acid or, more preferably, a borate/polyol complex... Agent: Alcon

20080089954 - Diagnosis and treatment of human dormancy syndrome: New methods for diagnosis of human dormancy syndrome are provided. Human dormancy syndrome is characterized by elevated serum ratio of rT3/fT3 compared to a population of normal subjects from which subjects suffering from fibromyalgia, chronic fatigue, obesity, dementias including Alzheimer's Disease and related dormancy conditions are excluded, and the presence... Agent: Borson Law Group, PC

20080089955 - Preparation and use for reducing the damaging effect of ammonia on organisms living in water: w

20080089956 - Nitric oxide in treatment of inflammation: A method of treating infectious inflammation in a mammal, including man, which comprises administering to a mammal in need of such treatment, nitric oxide, in the form of gaseous nitric oxide or a nitric oxide donor, in combination with a glucocorticoid, said combination being used in a therapeutically effective amount... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080089957 - Monocotyledon plant indications extract compositions, method of preparation and pharmaceutical compositions containing them: The present invention relates to a method for immuno-modulation in an organism by using a protein extract from a monocotyledon plant. The present invention also relates to a method for inhibiting nitrite production or anti-oxidation activity in an organism by using an organic extract from a monocotyledon plant. The present... Agent: Andrews & Kurth, L.L.P.

20080089958 - Topical and intravaginal microbicidal ad antiparsitic compositions comprising quassinoids or quassinoid-containing plant exrtracts: Pharmaceutical or dermo-cosmetic compositions for topical and intravaginal application for treatment of human and veterinary affections caused by anaerobic organisms or parasites are provided comprising quassinoids or plant extracts containing these phytochemicals, in effective amounts. Such compositions can be administered topically or intravaginally to patients in need thereof in various... Agent: Oliff & Berridge, PLC

20080089959 - Composition and uses of galectin antagonists: The present invention is directed to methods and compositions for augmenting treatment of cancers and other proliferative disorders. In particular embodiments, the invention combines the administration of an agent that inhibits the anti-apoptotic activity of galectin-3 (e.g., a “galectin-3 inhibitor”) so as to potentiate the toxicity of a chemotherapeutic agent.... Agent: Ropes & Gray LLP

20080089960 - Use of legume products for the treatment and prevention of radiotherapy-induced skin damage: The present invention features non-denatured legume products having trypsin inhibitory activity and reduced microbial content, methods of treating or preventing radiation-induced skin damage utilizing such legume products, compositions containing such legume products, and the topical application of such legume products or compositions to skin, nails, and hair.... Agent: Philip S. Johnson Johnson & Johnson

20080089961 - Compositions for enhancing immune function: The present invention is directed to compositions for enhancing immune function that include ingredients from natural sources. It is further directed to methods of administering the compositions and kits containing the compositions. In a composition aspect, the composition is for regulating immune function. It consists essentially of: 2 weight percent... Agent: Jeffrey A. Mckinney

20080089962 - Nutritional composition for facilitating muscle pumps: A nutritional composition, the consumption of which provides a method for creating and prolonging muscle pumps, providing a transducer effect for nitric oxide, increasing nutrient delivery and promoting increased vascular response in individuals. The nutritional composition of the present invention comprises citrulline, aspartic acid and. creatine. In addition, the nutritional... Agent: Fitzpatrick Cella Harper & Scinto

20080089963 - Topical compositions containing bacillus coagulans extracellular products and uses thereof: The present invention discloses compositions derived from an isolated Bacillus species spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture of said Bacillus coagulans strain, suitable for topical application to the skin or mucosal membranes of a mammal, which are utilized to inhibit... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080085237 - Weakly basic 2-nitroimidazoles for the non-invasive detection of tissue hypoxia: The present invention incorporates weakly basic substituents (pKa about 8 or greater) such as pyrrolidine, piperidine, piperazine and azapane moieties in halogenated 2-nitromidazoles as a major improvement over prior art for the non-invasive detection of cellular hypoxia in normal and malignant tissues. The invention features the use of [18F] positron... Agent: Clark & Elbing LLP

20080085247 - Composition of menthyl lactate and a mixture of menthol isomers: Described is a composition (i) comprising or (ii) essentially consisting of or (iii) consisting of (a) methyl lactate, (b) neomenthol, and (c) menthol, and optionally (d) neoisomenthol and/or (e) isomenthol, wherein said composition has a solidification point below +5° C.... Agent: Roylance, Abrams, Berdo & Goodman, L.l.p.

20080085246 - Use of eugenol acetate as an agent against bad breath: The use of eugenol acetate as an agent (i) for inhibiting and/or preventing the growth of and/or for killing microorganisms which cause bad breath and/or (ii) for combating bad breath is described.... Agent: Roylance, Abrams, Berdo & Goodman, L.l.p.

20080085249 - Artificial hair color removal compositions and methods: The invention relates to methods for removing artificial color from hair comprising combining a first composition comprising a sulfur reducing agent with a second composition comprising an oxidizing agent to form a color removing composition, and using the color removing composition to remove artificial color from the hair, as well... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080085255 - Aqueous fatty monoamine-containing anti-frizz composition for hair: The present invention is drawn to a composition and process for inhibiting hair from becoming frizzy when exposed to high and/or low humidity, the composition containing: (a) at least one fatty monoamine; (b) at least one nonionic surfactant; (c) at least one anionic silicone; (d) at least one water-insoluble material;... Agent: L'oreal Usa/ Patent Department

20080085254 - Aqueous phospholipid-containing anti-frizz composition for hair: The present invention is drawn to a composition and process for inhibiting hair from becoming frizzy when exposed to high and/or low humidity, the composition containing: (a) at least one phospholipid; (b) at least one nonionic surfactant; (c) at least one anionic silicone; (d) at least one water-insoluble material; (e)... Agent: L'oreal Usa/ Patent Department

20080085253 - Aqueous polyamine-containing anti-frizz composition for hair: The present invention is drawn to a composition and process for inhibiting hair from becoming frizzy when exposed to high and/or low humidity, the composition containing: (a) at least one fatty quaternary amine; (b) at least one nonionic surfactant; (c) at least one anionic silicone; (d) at least one water-insoluble... Agent: L'oreal Usa/ Patent Department

20080085258 - Aqueous polymaine-containing anti-frizz composition for hair: The present invention is drawn to a composition and process for inhibiting hair from becoming frizzy when exposed to high and/or low humidity, the composition containing: (a) at least one polyamine compound comprising at least three amino groups; (b) at least one nonionic surfactant; (c) at least one anionic silicone;... Agent: L'oreal Usa/ Patent Department

20080085257 - Composition and method for topical treatment of skin conditions: A composition for topically treating skin conditions consists essentially of a mixture of an amount of tricarboxylic acid, an amount of glycolic acid, and alcohol as the remainder of the composition. A method for treating skin conditions includes the steps of topically applying an effective amount of the composition to... Agent: Bliss Mcglynn, P.c.

20080085256 - Vitality restoring composition containing dhea and minoxidil: The present invention relates to a composition that reduces age related symptoms and provides increased energy and activity levels.... Agent: Orion Law Group

20080085260 - Formulation for repelling insects and attracting fish: Disclosed is a novel formulation and process for the effective repelling of insects without the adverse effects of repelling fish. Further the formulation is stable enough for long term storage, has a high rate of durability on the skin, and has been shown in cases to attract fish.... Agent: Carl D. Crowell

20080085263 - Liquid depot formulations: the present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or... Agent: Nixon & Vanderhye, Pc

20080085269 - Vaccine and method for treatment of neurodegenerative diseases: Methods and compositions are provided for treatment of neurodegenerative diseases in which there is accumulation of misfolded and/or aggregated proteins, excluding prion diseases. In particular, the invention relates to treatment of the neurodegenerative diseases Huntington's disease (HD), Alzheimer's disease (AD) or Parkinson's disease (PD), by administration of an agent selected... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080085270 - Coenzyme q10 formulation: The formula contains a combination of nutrients ideal for cardiovascular health. Coenzyme Q10 (CoQ10), tocotrienols and tocopherols (potent forms of vitamin E) promote healthy heart function, provide powerful antioxidant protection and support the immune system in its daily defense of the body. The formula also contains a unique tocotrienol complex,... Agent: Christopher J. Mcdonald Hoffman, Wasson & Gitler, P.c.

20080085239 - Aminoderivative of biotin and their conjugates with macrocyclic chelating agents: Formula (I) compounds are described where the groups are as defined here below, processes for their preparation, and their uses for the preparation of conjugates with radionuclides for use in human and animal therapy and diagnostics, particularly for the diagnosis and therapy of pathological conditions such as tumours.... Agent: Nixon & Vanderhye, Pc

20080085238 - Small molecules for imaging protein-protein interactions: A tissue is imaged to detect the presence of amyloid deposits or other target proteins prior to their aggregation into plaques, with the assistance of the administration of a labeled bifunctional compound of which one functionality binds to the target protein and the second functionality binds to a chaperone protein... Agent: Townsend And Townsend And Crew, LLP

20080085240 - Method and composition to evaluate cytochrome p450 2c19 isoenzyme activity using a breath test: The present invention relates, generally to a method of determining and assessing cytochrome P450 2C19-related (CYP2Cl9) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of 13CO2 exhaled by the subject upon intravenous or oral administration of a 13C-labeled CYP2C19 substrate compound. The... Agent: Foley & Lardner LLP

20080085241 - Antibody: The present invention provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of tumor specific binding proteins. In particular, the present invention provides an antibody which comprises at least one heavy chain variable region (VH) that comprises three CDRs, wherein said heavy chain... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080085242 - Non-viral gene delivery system: The present invention concerns a novel composition comprising a nucleic acid; and a chitosan containing branching groups covalently linked to the amino groups wherein said branches are selected from the following groups; alkyl with 2 or more carbon atoms, monosaccharides, oligosaccharides or polysaccharides. The composition is particularly useful as a... Agent: Connolly Bove Lodge & Hutz, LLP

20080085244 - Methods for identifying and using amyloid-inhibitory compounds: The present invention relates to identification of agents that pay a role in regulating brain amyloid-β (Aβ) levels in vivo. The invention provides compounds and methods of using such compounds to treat amyloidogenic conditions. It also provides a useful animal model for screening for and evaluating candidate amyloid inhibiting or... Agent: Wyeth C/o Darby & Darby, P.c.

20080085243 - Molecular markers for determining taxane responsiveness: The present invention provides a plurality of molecular markers and methods of using the markers for determining whether a cancer will be responsive to a taxane. Also provided are kits comprising the plurality of molecular markers.... Agent: Polsinelli Shalton Flanigan Suelthaus Pc

20080085245 - Topical anesthetic composition: A method for providing anesthesia to a subject having a wound, such as a laceration, a surgical incision, an ulcer, an abrasion or a burn, said method comprising the step of applying topically to the wound a composition comprising: at least one local anesthetic agent; a hydrophilic or hydroalcoholic gelling... Agent: Stefan Kirchanski

20080085248 - Controlled long acting release pharmaceutical preparation for use in the oral cavity: The present invention relates to a controlled long acting release pharmaceutical preparation for use in the oral cavity either for the treatment of diseases of the oral cavity or; for releasing said pharmaceutical preparation into said oral cavity. Said pharmaceutical preparation comprises at least a therapeutic agent, a binder and... Agent: Hershkovitz & Associates, Llc

20080085250 - Assortment of antiperspirants having varying product performance characteristics: An array of antiperspirant products, comprising a first antiperspirant product that is marketed to male consumers and marketed as clinical strength or prescription strength; and a second antiperspirant product that is marketed to female consumers and marketed as clinical strength or prescription strength.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080085252 - Composition for hair and body application: The inventive compositions comprise in a deionized water base A composition comprising: A preservative a chelating agent; one or more moisturizer and hydrolyzed keratin protein; an antioxidant selected from the group consisting of citric acid and a vitamin E salt; and an emulsifier-water trap selected from the group consisting of... Agent: Kenneth H. Tarbet

20080085251 - Hair processing agent and method for permanent waving hair: Provided are hair processing agents capable of permanent waving hair even at a neutral to weakly acidic pH range that causes less irritation to the skin, and hair processing agents in which an unpleasant odor is masked. Hair processing agents contain at least one compound represented by the formula (2).... Agent: Sughrue Mion, Pllc

20080085259 - Amine condensation polymers as phosphate sequestrants: Disclosed is a polymer or physiologically acceptable salt thereof. The polymer comprises a polymerized multifunctional amine monomer. The amine monomer comprises at least two amine groups and at least two acyclic nitrogen atoms that are connected through a —CH2CH2— group, provided that the amine monomer is not ethylenediamine or diethylenetriamine.... Agent: Genzyme Corporation Legal Department

20080085262 - Purified mammalian cytokines; related reagents and methods: CTLA-8 related antigens from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigens. Methods of using said reagents and diagnostic kits are also provided.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080085261 - Vaccine adjuvant: The present invention relates, in general, to a method of enhancing an immune response in a mammal and, in particular, to a method of enhancing an immune response to a vaccine comprising suppressing the number and/or function of regulatory T cells. The invention further relates to compounds and compositions suitable... Agent: Nixon & Vanderhye, Pc

20080085265 - System for optical stimulation of target cells: Stimulation of target cells using light, e.g., in vivo, is implemented using a variety of methods and devices. According to an example embodiment of the present invention, target cells are stimulated using an implantable arrangement. The arrangement includes an electrical light-generation means for generating light and a biological portion. The... Agent: Crawford Maunu Pllc

20080085266 - Target peptides for ovarian cancer immunotherapy: TADG-12 and CA125 are two proteins expressed with high specificity in ovarian cancer tumors. They thus would be potential antigens for immunotherapy in ovarian cancer. The invention is based on the discovery of peptides in TADG-12 and CA125 that can be used to induce an autologous T cell response that... Agent: Hugh Mctavish Cyr & Associates

20080085267 - Method for preventing or treating the development of respiratory allergies: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.... Agent: Bristol-myers Squibb Company - Mead Johnson

20080085268 - Use of lactobacillus farciminis for the prevention or treatment of digestive pathologies: The invention relates to the use of lactic bacteria of the species Lactobacillus farciminis for the treatment or prevention of a pathology of the digestive tube, especially an acute or chronic inflammatory pathology of the intestine.... Agent: Morgan Lewis & Bockius LLP

20080085264 - Methods for enhancing stem cell engraftment during transplantation: The present invention relates to the fields of hematopoietic stem cell transplantation and molecular biology. More specifically, methods for improving engraftment efficiency in stem cell transplants by improving stem cell homing to bone marrow are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20080085271 - Methods of preventing or treating cell-migration mediated conditions or diseases: The present invention relates to methods of identifying agents which modulate the activity of PIPKIγ661. Methods of using such agents to prevent or treat a cell migration-mediated condition or disease in a subject are also provided.... Agent: Foley & Lardner LLP

20080085272 - Silk-based drug delivery system: The present invention provides for novel sustained release silk-based delivery systems. The invention further provides methods for producing such formulations. In general, a silk fibroin solution is combined with a therapeutic agent to form a silk fibroin article. The article is then treated in such a way as to alter... Agent: David S. Resnick

20080085274 - Use of certain drugs for treating nerve root injury: The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNT-α comprising an effective amount of a metalloproteinase inhibitor, as well as a method for treatment of such disorders, and the use of metallo-proteinase inhibitors in the preparation of pharmaceutical composition for... Agent: Fish & Richardson Pc

20080085273 - Vehicle for the transport of a chosen molecule to a cell: Vehicle for the transport of a chosen molecule to a cell, comprising a SAINT-molecule which is bound to the chosen molecule by means of an electrostatic interaction, in which the SAINT-molecule is coupled to the linker molecule and the linker molecule is coupled to the cell specific ligand and in... Agent: Peacock Myers, P.c.

20080085275 - Methods of modulating apoptosis by administration of relaxin agonists or antagonists: The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides methods of modulating apoptosis by administering a relaxin agonist or antagonist... Agent: Townsend And Townsend And Crew, LLP

20080085276 - Method of treating eye injury with local administration of a vegf inhibitor: Methods of reducing or treating angiogenesis and/or inflammation associated with eye injury in a subject in need thereof, comprising administering an agent capable of blocking or inhibiting vascular endothelial growth factor (VEGF) are provided. The methods are useful for inhibiting or ameliorating eye injury, particularly acute or subacute corneal injury... Agent: Regeneron Pharmaceuticals, Inc

20080085277 - Novel antigen-binding polypeptides and their uses: Novel antigen-binding polypeptides (ABP) and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080085278 - Binding member which binds to both lewis-y and lewis-b haptens, and its use for treating cancer: The invention relates to the use of a binding member which binds to Lewisy and Lewisb haptens in the treatment of tumours and leukaemia. The binding member may be an antibody which binds to Lewisy and Lewisb haptens and cancer cells and induces cells death.... Agent: Bozicevic, Field & Francis LLP

20080085279 - Cancer treatment: The present invention relates to the inhibitors of MDM2 Binding Protein (MTBP) activity that may be used as medicaments. Such medicaments may be used to prevent or treat cancers. A preferred inhibitor is an siRNA molecule that is specific for silencing MTBP expression. The invention further relates to screening methods... Agent: Davis Wright Tremaine LLP/los Angeles

20080085280 - Monovalent ligand of the fcalphari receptor as an anti-inflammatory agent: The invention relates to the use of a monovalent antibody fragment directed against the EC2 domain of the FcαRI receptor for the treatment of inflammatory diseases.... Agent: Merchant & Gould Pc

20080085281 - Inhibitors of dkk-1: The present invention encompasses methods and compositions for enhancing the growth of adult marrow stromal cells. The present invention also encompasses methods and compositions for regulating the effects of Dkk-1. Methods and compositions for treatment of osteolytic lesions in multiple myeloma and enhancing osteogenesis are also included.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080085282 - Methods of detecting and controlling mucoid pseudomonas biofilm production: Compositions and methods for detecting and controlling the conversion to mucoidy in Pseudomonas aeruginosa are disclosed. The present invention provides for detecting the switch from nonmucoid to mucoid state of P. aeruginosa by measuring mucE expression or MucE protein levels. The interaction between MucE and AlgW controls the switch to... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080085283 - Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders: Methods and compositions for the development of effective cancer therapies using mitotic inhibitors which have limited general toxicity to normal, non-cancerous cells and tissues are provided. The methods and compositions utilize cytotoxic compounds comprised of a cell-binding agent (e.g., antibodies) conjugated to an anti-mitotic compound (e.g., maytansinoids). The invention further... Agent: Heller Ehrman LLP

20080085284 - Construction of a comparative database and identification of virulence factors comparison of polymorphic regions in clinical isolates of infectious organisms: The present invention is directed to novel nucleotide sequences to be used for diagnosis, identification of the strain, typing of the strain and giving orientation to its potential degree of virulence, infectivity and/or latency for all infectious diseases more particularly tuberculosis. The present invention also includes method for the identification... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080085285 - Use of recombinant heat shock protein complexed to kidney cancer antigen: A heat shock protein in combination with carbonic anhydrase IX and a method for improving immune response to carbonic anhydrase IX in a mammal by complexing it with a heat shock protein prior to administration to the mammal.... Agent: Michael L. Dunn

20080085286 - Aspergillus vaccine preparation and methods of making and using thereof: The present invention relates to compositions and methods in preventing and/or treating diseases caused by Aspergillus. In particular, the present invention is directed to Aspergillus vaccine preparations and methods of making and using thereof.... Agent: Perkins Coie LLP

20080085287 - Food additve: Agent containing a yeast derivative comprising 5′-nucleotides and/or peptides of at least 1000 daltons useful for the prevention and/or treatment of cannibalism in livestock, the preparation and the use thereof.... Agent: Sughrue Mion, Pllc

20080085288 - Method of immunization against the 4 dengue serotypes: e

20080085289 - Immunogenic composition: The present application relates to immunogenic compositions comprising a mixture of staphylococcal antigens which combines antigen having different functions, for instance, combinations including a staphylococcal extracellular component binding protein and a staphylococcal transporter protein or a staphylococcal extracellular component binding protein and a staphylococcal regulator of virulence or toxin or... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080085290 - Skin cooling compositions: Provided is a temperature change composition including a neurosensory component; and a first phase change component having a first phase change temperature between about 15 degrees C. and about 40 degrees C. Also provided is a temperature change composition including an evaporative cooling component; and a first phase change component... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf

20080085291 - Solid cosmetic and therapeutic compositions applicable to the human skin and gellable on contact with water: Solid compositions applicable to the human skin and gellable on contact with water. These compositions are prepared in the form of a flexible solid film and can be used for cosmetic and/or therapeutic purposes. The compositions contain hyaluronic acid, a very fine inert powder and a small quantity of water... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080085292 - Composite scaffolds seeded with mammalian cells: Implantable, biocompatible scaffolds containing a biocompatible, porous, polymeric matrix, a biocompatible, porous, fibrous mat encapsulated by and disposed within said polymeric matrix, and a plurality of mammalian cells seeded within said tissue scaffold. The invention also is directed to methods of treating disease or structural defects in a mammal utilizing... Agent: Philip S. Johnson Johnson & Johnson

20080085294 - Apparatuses and methods to treat atherosclerotic plaques: This invention comprises an apparatus for treating an atherosclerotic plaque in a coronary artery of a mammal by placing at or proximate to an entrance to the coronary artery and upstream of the vulnerable plaque, and an effective amount of a therapeutic agent for the treatment of the plaque. This... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080085293 - Drug eluting stent and therapeutic methods using c-jun n-terminal kinase inhibitor: The present invention relates to a system and device for preventing stenosis and/or restenosis after an invasive procedure in a body vessel or cavity having an inner wall surface, the system comprising inserting a device coated with a growth arresting, lipid-derived, bioactive substance at a desired location along the inner... Agent: Roger A. Gilcrest

20080085296 - Methods for reduction of post operative ileus.: An apparatus and method for reducing post-operative ileus and/or gastric stasis is described. The method can include applying to the intestine a therapeutically effective amount of a composition comprising a drug that is effective in reducing post-operative ileus and/or gastric stasis, such as by introducing the composition through a surgical... Agent: Philip S. Johnson Johnson & Johnson

20080085295 - Hydrogels containing low molecular weight alginates and biostructures made therefrom: The present invention is directed to a hydrogel comprising an alginate having a low molecular weight (e.g., less than 75,000 Daltons), wherein the alginate is present in a high concentration (e.g., greater than 2.5% by weight of the hydrogel). The present invention is also directed to methods of making and... Agent: Patent Administrator Fmc Corporation

20080085297 - Bioabsorbable device having encapsulated additives for accelerating degradation: A medical device has a structure made of one biodegradable and/or bioabsorbable material. A degradation additive is encapsulated by another biodegradable and/or bioabsorbable material forming a nanoparticle or microparticle. The nanoparticle or microparticle is together with the one biodegradable and/or bioabsorbable material of the structure. The other biodegradable and/or bioabsorbable... Agent: Philip S. Johnson Johnson & Johnson

20080085298 - Rapid mucosal gel or film insulin compositions: Gel, powder, suspension, emulsions or film formulations for systemic delivery of insulin with improved stability and rapid onset of action are described herein. The formulations are preferably absorbed to a mucosal surface, most preferably via buccal or sublingual administration, although rectal, vaginal, nasal or ocular administration is possible. The formulations... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080085299 - Peptides derived from colostrinin: The amino acid sequence of several peptides is disclosed. These peptides are useful, inter alia, in the treatment of disorders of the immune system and the central nervous system, and are also useful as food additives.... Agent: Rankin, Hill & Clark LLP

20080085300 - Hemostatic compositions and method of manufacture: A composition for promoting hemostasis is defined by a substrate in particle or pellet form and a hemostatic agent disposed on the substrate such that when using the composition to treat a bleeding wound, contacting the bleeding wound with the hemostatic agent causes blood to clot. The hemostatic agent may... Agent: Michaud-duffy Group LLP

20080085301 - Method for transdermal administration of antimicrobial medications: The present invention relates to methods and compositions for improved efficacy and delivery of time-dependent antimicrobial drug compositions to a patient. Transdermal dosage forms and methods for steady-state delivery of drug to produce and maintain a serum concentration of drug above the minimum inhibitory concentration or minimum microbicidal concentration are... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080085302 - Transdermal device for administration of antimicrobial medications: The present invention relates to methods and compositions for improved efficacy and delivery of time-dependent antimicrobial drug compositions to a patient. Transdermal dosage forms and methods for steady-state delivery of drug to produce and maintain a serum concentration of drug above the minimum inhibitory concentration or minimum microbicidal concentration are... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080085303 - Robust sustained release formulations of oxymorphone and methods of use thereof: Robust sustained release formulations, solid dosage forms comprising robust sustained release formulations, and methods for making and using these formulations and solid dosage forms are provided. Robustness of the sustained release formulation is related to the particle size of the hydrophilic gum. Sustained release formulations resist dose-dumping when ingested with... Agent: Wilmerhale/boston

20080085304 - Robust sustained release formulations: Robust sustained release formulations, solid dosage forms comprising robust sustained release formulations, and methods for making and using these formulations and solid dosage forms are provided. Robustness of the sustained release formulation is related to the particle size of the hydrophilic gum. Sustained release formulations resist dose-dumping when ingested with... Agent: Wilmerhale/boston

20080085305 - Robust sustained release formulations of oxymorphone: Robust sustained release formulations, solid dosage forms comprising robust sustained release formulations, and methods for making and using these formulations and solid dosage forms are provided. Robustness of the sustained release formulation is related to the particle size of the hydrophilic gum. Sustained release formulations resist dose-dumping when ingested with... Agent: Wilmerhale/boston

20080085306 - Topiramate compositions and methods of enhancing its bioavailability: The present invention is directed to pharmaceutical compositions that allow for once-daily or alternate day dosage forms of topiramate. The proposed delayed/extended release single dosage form is equivalent to the immediate-release multiple dose daily regimen, and upon administration, provides steady state blood levels of topiramate. Formulations with increased bioavailability and... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080085307 - Paired/matched medication: This patent pairs/matches medication components. This may help with more accurate dosing when the need arises to split tablets. Also there may be increased patient compliance with patients taking many medications. Additionally, this patent would function competition to combination patents, thus driving down the cost for consumers.... Agent: Dr. Renjit Sundharadas, M.d.

20080085308 - Granules comprising paracetamol, a nsaid and a sugar alchohol made by melt extrusion: A pharmaceutical composition comprising a granular component comprising a plurality of solidified melt granules of a sugar alcohol having a salt of a non-steroidal anti-inflammatory drug (NSAID salt) and paracetamol contained therein.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080085309 - Rapidly disintegrating tablets in buccal cavity and manufacturing method thereof: A rapidly disintegrating tablet in the buccal cavity, comprising a drug, a treated starch having a degree of gelatinization of 30% to 60%, and a saccharide, and a process for manufacturing the same comprising the steps of mixing a drug, a treated starch having a degree of gelatinization of 30%... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080085310 - Capecitabine rapidly disintegrating tablets: There is provided a film coated pharmaceutical composition comprising 5′-deoxy-5-fluoro-N-[(pentyloxy)-carbonyl]-cytidine (capecitabine) and at least one disintegrant selected from the group comprising of crospovidone (particle size <15-400μ), croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropylcellulose, Pharmaburst C or any combination of these, together with other pharmaceutically acceptable excipients to form a rapidly... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080085311 - Antihistamine-decongestant combinations: Multi-particulate pharmaceutical compositions comprising an antihistamine for immediate release and a decongestant for modified release.... Agent: Dr. Reddy's Laboratories, Inc.

20080085312 - Multi-phase release potassium guaiacolsulfonate compositions: Formulations have been developed administering a guaiacolsulfonate salt, preferably potassium salt, in multi-phases. In a preferred embodiment, the formulation contains potassium guaiacolsulfonate in an immediate release (“IR”) form and a sustained or delayed release (“DR”) form and/or pulsed release (“PR”) form. In another embodiment, the potassium guaiacolsulfonate is released in... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080085313 - Methods and compositions for treatment of sleep apnea: Provided herein are methods of treatment of sleep apnea by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof to a patient in need of the treatment.... Agent: Jones Day

20080085314 - Solid oral formulations for combination therapy: A first, solid oral pharmaceutical composition includes an extended release acetaminophen, a non-steroidal anti-inflammatory drug, such as naproxen or ibuprofen, and a third drug capable of reducing gastric acid secretion, such as ranitidine or omeprazole. A second, solid oral pharmaceutical composition includes a non-steroidal anti-inflammatory drug and an agent for... Agent: Leigh P. Gregory

20080085315 - Amorphous ezetimibe and the production thereof: Ezetimibe compositions of enhanced bioavailability are described that contain ezetimibe with at least one solubility-enhancing polymer. Described methods to produce the bioenhanced products comprise solvent spray drying. One aspect of the method includes the steps of providing a mixture comprising ezetimibe, a solubility-enhancing polymer and a single solvent, a solvent... Agent: International Specialty Products Attn: William J. Davis, Esq.,

20080085316 - Dry hemostatic compositions and methods for their preparation: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has... Agent: Baxter Healthcare Corporation

20080085317 - Method and formulation for treating resistance to antihypertensives and related conditions: A method for the prevention or treatment of symptoms of hypertension in a patient who is resistant to antihypertensive effects of an antihypertensive compound administered in the absence of melatonin comprises administering to said patient melatonin in an amount effective to ameliorate or prevent symptoms of hypertension in said patient.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080085318 - Coated compositions and methods for preparing same: The present invention provides methods for preparing a coated pharmaceutical composition comprising the steps of a) providing a pharmaceutically active agent or a nutraceutical; b) providing a solution or a dispersion of a polyvinyl-based, cellulose-based, acrylate-based, or shellac polymeric coating composition, and mixtures thereof, in a solvent selected from the... Agent: Richard R. Muccino

20080085319 - Lipids containing omega-3 and omega-6 fatty acids: A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein... Agent: Fleit Kain Gibbons Gutman Bongini & Bianco

20080085320 - Lipids containing omega-3 and omega-6 fatty acids: A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidyicholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein... Agent: Fleit Kain Gibbons Gutman Bongini & Bianco

20080085321 - Agent for preventing or suppressing hepatopathy and functional food for preventing or suppressing hepatopathy: The present invention provides an agent for preventing or suppressing hepatic dysfunction which may be taken daily and continuously, has excellent safety, and is capable of effectively preventing and/or suppressing hepatic dysfunction, such as hepatocellular necrosis, and functional food, such as foods for specified health uses, for preventing or suppressing... Agent: Sughrue Mion, Pllc

20080085322 - Methods and compositions for activating regenerative stem cells from bone marrow: The present invention provides novel compositions and methods for pharmaceutical or nutraceutical use in an animal, preferably in a human. In one aspect, compositions and methods are provided for activating regenerative stem cells from bone marrow, which can lead to enhanced proliferation of hematopoietic cells and immune functions of the... Agent: Wilson Sonsini Goodrich & Rosati

20080085323 - Product and methods for diagnosis and therapy for cardiac and skeletal muscle disorders: Disclosed are products and methods to promote myoblast activation and cardiac and skeletal muscle growth or regeneration, and to treat heart and skeletal muscle diseases, based on the identification of cellular processes affected by prelamin A processing.... Agent: Sheridan Ross Pc

20080085324 - Compositions and methods for detecting and treating renal injury and inflammation: Renal injury and inflammation is diagnosed by detecting an elevation in GSK3b level or activity. Inflammation of bodily tissues such as renal tissue is inhibited by administration of GSK3b inhibitory compositions.... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080085325 - Dialysis solution, formulated and stored in two parts, comprising phosphate: The present invention relates to a medical solution. According to the invention the ready-for-use solution comprises phosphate in a concentration of 1.0-2.8 mM, is sterile and has a pH of 6.5-7.6. The present invention further relates to a method for producing the medical solution and the use thereof.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080085326 - Antimicrobial material compositions enriched with different active oxygen species: This invention discloses novel antimicrobial materials comprising of nanocrystalline metal, metal oxide, and active oxygen species in a permeable structure. It also discloses the compositions of the inventive material enriched with different active oxygen species. The inventive material showed a strong antimicrobial ability over a wide spectrum of microbies. The... Agent: Hai Xiong Ruan

20080085327 - Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses: Described is an intra-mammary teat sealant and a corresponding method of forming a physical barrier in the teat canal of a non-human animal for prophylactic treatment of mammary disorders during the animal's dry period. The method includes the step of infusing a bismuth-free teat seal formulation into the teat canal... Agent: Intellectual Property Department Dewitt Ross & Stevens S.c.

20080085328 - Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof: The present invention also relates to the discovery that compound 1R, substantially free from the corresponding (S)-stereoisomer, is an activator of caspases and inducer of apoptosis, as well as an antivascular agent. Therefore, compound 1R, substantially free from the corresponding (S)-stereoisomer, can be used to induce cell death in a... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080085329 - Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms: The present invention concerns the use of oxygen antagonists for inducing stasis in cells, tissues, and/or organs in vivo or in an organism overall. It includes methods and apparatuses for achieving stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, therapeutic methods... Agent: Fulbright & Jaworski L.l.p.

20080085330 - Compounds for stimulating stem cell proliferation including spirulina: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of substances selected from blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3, Spirulina, AFA or effective combinations and derivatives of these.... Agent: Christopher Paradies, Ph.d.

20080085331 - Composition and method for raising blood glucose level: m

20080085332 - Methods and compositions for improving cardiovascular risk factors and metabolic risk factors that cause syndrome x: The present invention provides for compositions and related methods using extracts from the Cissus quadrangularis plant to improve and eliminate various cardiovascular risk factors and metabolic risk factors that cause Syndrome X. Controlled university studies demonstrated that 300 mg Cissus quadrangularis plant extract provided to obese humans daily for six... Agent: Greenberg Traurig LLP (la)

20080085333 - Composition comprising extract of anemarrhena asphodeloides and aralia elata,and use thereof: The present invention relates to a composition comprising a water or organic solvent extract of Anemarrhena asphodeloides and Aralia elata, and the use thereof. The composition has a preventive or therapeutic effect on inflammatory skin diseases and an antibacterial effect against Propionibacterium acnes.... Agent: Buchanan, Ingersoll & Rooney Pc

20080081019 - Marker for tardive dyskinesia: The present invention discloses markers for tardive dyskinesia. Also disclosed is a method of determining the risk of tardive dyskinesia from antipsychotic medication in a subject, the method comprising the step of genotyping a sample obtained from the subject for the rs905568 polymorphism, wherein a subject comprising a CC, CG... Agent: Suzannah K. Sundby Smith, Gambrell & Russel, LLP

20080081021 - Manganese-enhanced magnetic resonance imaging of neurons using electrical stimulation: A method for improving uptake of contrast agents, such as manganese-based contrast agents, is neuronal imaging of areas such as the spinal cord and cortical spinal tract with magnetic resonance imaging are provided. Electrical stimulation is applied to the subject in order to increase uptake of the contrast agent in... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20080081020 - Color change surgical prep solution: This invention discloses a surgical prep solution formulation, either film forming or non-film forming, that changes color upon a change in pH to indicate that the solvent has sufficiently evaporated. The major components of this surgical prep solution include: antimicrobial agents, solvents, pH adjusters, color changing pH indicators, and optionally:... Agent: Allegiance Corporation Attn: Kim Luna

20080081022 - Poss containing cosmetic compositions having improved wear and/or pliability and methods of making improved cosmetic compositions: Film-forming and cosmetic compositions containing a combination of certain polyhedral oligomeric silsesquioxanes (POSS) and non-POSS silicone resins are described, the combination providing improved wear and/or pliability properties over previous silicone resin containing compositions. Typically, the advantageous combinations will be formulated in a cosmetic composition that contains at least one solvent,... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080081023 - Oral compositions containing gel networks: The present invention is directed to an oral composition containing a gel network phase comprising: (i) one or more fatty amphiphiles, (ii) one or more surfactants, and (iii) one or more solvents; and an oral carrier phase. In certain embodiments, the gel network is used to structure the oral composition.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080081024 - Photoprotective compositions comprising synergistic combination of sunscreen active compounds: Compositions for topical application to skin and/or hair, comprising photoprotecting synergistically effective amounts of sunscreen active agents octinoxate, octocrylene, and amiloxate; methods of protecting skin and/or hair against deleterious effects of sunlight/UV radiation by topical application of compositions.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080081025 - Uv absorbing chromophores covalently bonded to hyperbranched polymers: m

20080081027 - Concealer composition: Disclosed is a concealer composition comprising by weight from about 30% to about 99% of powders, the powders comprising by weight of the entire composition; (a) from about 0.1% to about 74.9% of a titanium coated pigment made of a core pigment and a titanium dioxide coating, the amount of... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080081026 - Cosmetic product: Disclosed is a cosmetic product comprising: (a) a foundation comprising less than about 15% by weight of the foundation of a high coverage pigment selected from the group consisting of titanium dioxide, zinc oxide, and mixtures thereof; and (b) a concealer comprising at least about 25% by weight of the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080081028 - Pressed powder composition: Disclosed is a pressed powder composition having comprising by weight: (a) from about 75% to about 99% of a powder comprising: (1) at least 25% by weight of the entire composition of a high coverage pigment selected from the group consisting of titanium dioxide, zinc oxide, and mixtures thereof, (2)... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080081029 - Surface-treating agents, surface-treated powders, and cosmetics comprising the same: s

20080081030 - Termite bait and processes related thereto: A termite bait comprising cellulose, at least one sugar, and at least one acid is provided. This termite bait can further comprise at least one insecticide. Furthermore, this termite bait can be encased in or contained in a durable material. Additionally, a process to make such termite baits is provided.... Agent: Dow Agrosciences LLC

20080081034 - Topical skin compositions, their preparation, and their use: Topical skin compositions include a complex containing components to provide a defense against the various pathway mechanisms of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. The compositions may be administered by topically applying them in an amount to... Agent: In Re: Alticor Inc. 28533 Brinks, Hofer, Gilson & Lione

20080081035 - Therapeutic protease compositions: A method of treating an inflammatory condition involving TNF-α in a mammal by administering to a patient a composition with an effective amount of an isolated alkaline protease in an amount effective to inactive TNF-α. The invention also involves compositions, including pharmaceutical compositions containing an isolated alkaline protease in an... Agent: Hunton & Williams LLP Intellectual Property Department

20080081031 - Use of pegylated il-10 to treat cancer: Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.... Agent: Dnax Research Inc. Legal Department

20080081032 - Method for reducing pain using oncolytic viruses: The present invention provides a method for reducing pain associated with neoplasms in a mammal, comprising administering an effective amount of one or more oncolytic viruses. Preferably, the mammal also receives an analgesic, and the amount of analgesic required by the mammal is reduced when the oncolytic virus is administered.... Agent: Fish & Richardson P.C.

20080081033 - Preparation of a cell concentrate from a physiological solution: The present invention is directed to methods and compositions regarding the preparation of an cell concentrate, such as, for example, an osteogenic cell concentrate, from a physiological solution, such as bone marrow aspirate, blood, or a mixture thereof. In specific embodiments, the invention provides methods and compositions utilizing two physiological... Agent: Fulbright & Jaworski, LLP

20080081036 - Formulation and method for a shampoo for animals: Animal shampoo compositions and methods of using the same for topical treatment of pets in need of improvement of quality of skin are provided. Methods for preparing such shampoos are also provided.... Agent: Dla Piper US LLP

20080081037 - Methods and agents for diagnosis and prevention, amelioration or treatment of goblet cell-related disorders: The present invention inter alia relates to methods for the prevention, amelioration or treatment of medical conditions associated with an alteration in normal goblet cell function. It also relates to methods of screening for disease-relevant markers indicative of an increased risk of a subject of developing such a condition. It... Agent: Fish & Richardson PC

20080081038 - Novel antigen-binding polypeptides and their uses: Novel antigen-binding polypeptides (ABP) and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080081039 - Inorganic selenium for treatment of cancer: The present invention discloses the use of selenate or its pharmaceutically acceptable salts, especially in supranutritional amounts, in methods and compositions for inhibiting the growth or proliferation of tumor cells. The present invention also discloses the use of selenate or its pharmaceutically acceptable salts in combination with one or both... Agent: Knobbe Martens Olson & Bear LLP

20080081040 - Methods for treating bone cancer pain by administering a nerve growth factor antagonist: The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF.... Agent: Morrison & Foerster LLP

20080081041 - Method of using il6 antagonists with mitoxantrone for prostate cancer: The invention is directed to a method of treating a subject diagnosed with prostate cancer which comprises co-administering mitoxantrone in combination with an IL-6 antagonist.... Agent: Philip S. Johnson Johnson & Johnson

20080081042 - Passive immunization and methods of treament for anthrax using antibodies: A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method... Agent: Knobbe Martens Olson & Bear LLP

20080081043 - Nk cell activation inducing ligand (nail) dna and polypeptides, and use thereof: The invention is directed to purified and isolated novel NAIL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080081044 - Compositions and methods for generation of infectious hepatitis c virus in immortalized human hepatocytes: The present invention provides a cell line capable producing infectious hepatitis C virus 1a (HCV 1a) particles in culture. Disclosed are compositions and methods for an HCV 1a (clone H77) transfected immortal human hepatocyte (IHH) capable of generating infectious HCV 1a virus particles in culture. Also disclosed are methods of... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20080081045 - Combination therapy for cancer: Anti-hormonal (anti-estrogenic steroid) therapy and immunotherapy are used in combination to treat breast cancer. The preferred immunotherapeutic agent is an immunogen, preferably comprising sialyl-Tn, and more preferably is a sialyl-Tn/KLH conjugate.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080081046 - Multiple sclerosis synergistic phyto-nutraceutical composition: A Phytoceutical composition for the prevention and treatment of Multiple Sclerosis (MS) and symptoms is provided. A specific combination of extracts of plants and nutraceuticals is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting... Agent: Jose Olalde Rangel

20080081047 - Anti-sars monoclonal antibodies: Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterisation of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the... Agent: Ade & Company Inc.

20080081048 - Production of modified neurotoxins: The invention provides improved methods of making compositions comprising detoxified neurotropically active modified neurotoxins derived from snake venom, and compositions made using these methods. The compositions are useful for the treatment of a wide variety of neurological and viral diseases.... Agent: Robert J. Van Der Wall Gables One Tower

20080081049 - Treatment of fine wrinkles with clostridia neurotoxins: Methods of using clostridial toxins and other biological agents to thin skin and control fine wrinkles in humans are provided. In preferred embodiments the methods provide beneficial effects in humans.... Agent: Omri M. Behr

20080081050 - Vaccine against streptococcus pneumoniae: The present invention relates to a combination of 2 or more S pneumoniae proteins, their manufacture and use in medicine as a vaccine. Such combinations are particularly useful for the protection of infants and elderly against streptococcal infection.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080081051 - Method of manufacturing anti-tumor and anti-viral compositions: An anti-cancer composition having biocompatible materials, which can selectively exploit chemical variations between normal cells and cancer cells to inhibit or prevent the proliferation of cancerous cells and methods of use.... Agent: Alfred M. Walker

20080081052 - Topical compositions containing solubilized allantoin and related methods: A method for enhancing solubility of allantoin in an aqueous vehicle using a solubilization enhancer is described. Aqueous compositions containing the solubilized allantoin at a level of 0.5% by weight or higher are able to be obtained by using urea or urea derivatives as the solubilization enhancer. The aqueous topical... Agent: Jerry Zhang

20080081053 - Treatment method: A method for treating AML is disclosed which comprises administering an mTOR inhibitor to a patient in need thereof.... Agent: Ariad Pharmaceuticals, Inc. Ariad Gene Therapeutics, Inc.

20080081054 - Aqueous nail polish film: m

20080081057 - Composition having a healthy appearance effect: Composition containing at least one encapsulated pigment and at least one skin colouring agent chosen from self-tanning agents, melanogenesis activators and their mixtures. The composition of the invention constitutes in particular a cosmetic composition which gives an immediate healthy appearance effect which lasts over time.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080081056 - Depolymerized polysaccharide-based hydrogel adhesive and methods of use thereof: The present invention provides novel polysaccharide-based adhesive hydrogel compositions useful for wound healing and topical and transdermal delivery of therapeutic and cosmetic agents, methods of preparation and uses thereof. The hydrogel includes modified polysaccharides which bestow superior cohesion and adhesiveness to the hydrogel. The present invention further provides methods and... Agent: Winston & Strawn LLP Patent Department

20080081055 - Film with improved dissolution, cosmetic product: Water-soluble anhydrous film containing (i) at least one water-soluble or water-dispersible film-forming polymer, (ii) at least one polysaccharide thickening agent, (iii) at least one water-soluble or water-dispersible oxyalkylenated polysiloxane and (iv) one or more plasticizers chosen from polyols. The invention also relates to the product obtained by mixing at least... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080081058 - Composition for promoting vascular smooth muscle relaxation: A composition for topical application to a part of the body comprises a vasodilator, for example glyceryl trinitrate, as active ingredient dissolved in a blend of volatile and non-volatile solvents of different solvating capacities for the vasodilator. The vasoldator is present in the composition at a concentration at or slightly... Agent: Clark & Brody

20080081059 - Synergistic matrix composite for making stable microemulsions of active ingredients: What is described herein is a synergistic matrix composite for making a stable microemulsion in water of an active ingredient comprising a first matrix composition including by wt. (a) 5-30% of a C8-C18 N-alkyl pyrrolidone, (b) optionally, 5-60% of a water insoluble organic solvent soluble therein, (c) 30-70% of a... Agent: Attn: William J. Davis, Esq. International Speciality Products

20080081060 - Chitosan-coated calcium sulfate based medicament delivery system: A biodegradable medicament delivery system comprising a multi-layered calcium-sulfate based drug delivery vehicle. The vehicle comprises a calcium sulfate center or core with the medicament or medicaments, encased in one or more layers of chitosan. The chitosan may be cross-linked with a cross-linking agent. The vehicle may comprise any suitable... Agent: W. Edward Ramage

20080081061 - Composite for implantation in the body of an animal and method for making the same: Composites that include a ceramic substance disposed in a polymeric material and associated methods for making the same.... Agent: Barnes & Thornburg LLP

20080081062 - Medical apparatus and method for producing same: A medical device that includes at least one antibiotic in a macromolecular substance that swells upon contact with a solvent. Also, a method for preparing an antibiotic-containing medical device that involves contacting a medical device having at least a portion of the surface formed from a swellable macromolecular substance, with... Agent: Kendall (cdfs)

20080081063 - Polymer blend-bioceramic composite implantable medical devices: Methods and devices relating to polymer blend/bioceramic composite implantable medical devices are disclosed.... Agent: Squire, Sanders & Dempsey LLP

20080081064 - Implantable medical device with apertures for delivery of bioactive agents: An implantable medical device for the release of bioactive agents at desired rates is described. The device includes a body member with two or more aperture sets and an inner space. The bioactive agents are arranged within the inner space of the body member so that each bioactive agent present... Agent: Kagan Binder, PLLC

20080081065 - Materials and methods for inhibiting wip1: Isolated or purified oligonucleotides and isolated or purified morpholino oligomers; a method of detecting cancer or a predisposition to cancer in a mammal, comprising comparing the level of expression of Wip1 in the mammal to a control; a method of treating cancer in a mammal that expresses the same or... Agent: Leydig, Voit & Mayer, Ltd.

20080081066 - Tea-derived compositions and methods of using same for cardiovascular health: Disclosed herein are compositions comprising tea derived components which are useful in decreasing elevated blood pressures, lowering LDL and/or lowering inflammatory markers of cardiovascular disease. Specifically exemplified herein are compositions comprising predetermined amounts of L-theanine and EGCG, and methods of using same to improve cardiovascular health.... Agent: Beusse Wolter Sanks Mora & Maire

20080081067 - Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof: The invention relates to sustained release pharmaceutical compositions of venlafaxine, process for preparing such compositions and method of using such compositions. Preferably, it relates to a sustained release pharmaceutical composition of venlafaxine comprising a first sustained release portion and a second sustained release portion wherein the first and the second... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20080081068 - Modified release formulations of a bupropion salt: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080081069 - Novel controlled release formulations of divalproex sodium: A controlled release formulation comprising less than about 40% of anti-epileptic drug, about 20% to about 50% of rate controlling polymer and silica having a particle size less than about 1 micron and specific surface area not less than 70 m2/g, all weight percentages are based upon the total weight... Agent: Merchant & Gould PC

20080081070 - Pharmaceutical formulation with enhanced solubility for the delivery of corticosteroids: Formulations have been developed to improve the solubility of corticosteroids such as fluticasone proprionate in a composition designed to achieve localized release of the drug in the small intestine and/or colon. In one embodiment, solid dispersions of fluticasone are prepared wherein the drug is blended with or coated onto a... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080081071 - Film embedded packaging and method of making same: The present invention relates to packaging in the form of a pouch, which may contain active substances, such as food products, pharmaceutical agents, nutraceuticals and cosmetic agents, or the like. More specifically, in some embodiments, the present invention provides a pouch, which includes at least one porous substrate encompassing a... Agent: Hoffmann & Baron, LLP

20080081072 - Resin-complex granulation for water-soluble drugs and associated methods: The present invention provides methods for preparing pharmaceutical resin-complexed granules which are taste-masked or capable of providing modified release of a water-soluble drug comprising the steps of (a) dissolving a water-soluble drug in water to form a solution; and (b) granulating the drug solution from step (a) in the presence... Agent: Richard R. Muccino

20080081073 - Adsorbent for an oral administration, and agent for treating or preventing renal or liver disease: An adsorbent for an oral administration, comprising a surface-modified spherical activated carbon wherein an average particle diameter is 50 to 200 μm, a specific surface area determined by a BET method is 700 m2/g or more, a bulk density is less than 0.54 g/mL, a total amount of acidic groups... Agent: Reed Smith LLP

20080081074 - Polymers for functional particles: The present invention generally relates to polymers and macromolecules, in particular, to block polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly... Agent: Wolf Greenfield & Sacks, P.C.

20080081075 - Multifunctional mixed micelle of graft and block copolymers and preparation thereof: The present invention discloses a novel mixed micelle structure with a functional inner core and hydrophilic outer shells self-assembled from a graft macromolecule and one or more block copolymer, and preferably from a graft copolymer and two or more diblock copolymers. The micelle synthesized in the present invention has a... Agent: Bacon & Thomas, PLLC

20080081076 - Nanofraction immune modulators, preparations and compositions including the same, and associated methods: Compositions that include extracts from sources of immune modulators that include nanofraction immune modulator molecules (i.e., molecules having molecular weights of about 3,000 Da and less) are disclosed. These compositions may also include other immune modulators, such as transfer factor. Administration of compositions with extracts that include nanofraction immune modulator... Agent: Trask Britt

20080081077 - Method of wound/burn healing using copper-zinc compositions: Composition and methods for alleviating or eliminating wounds and/burns by providing an effective amount of one or more copper, zinc and copper-zinc compositions are disclosed. Treatment is accomplished through the use of topical compositions containing one or more copper or zinc salts and/or copper-zinc compounds or complexes, particularly copper-zinc malonate... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20080081078 - Prevention of cell proliferation by inhibiting myosin light chain kinase: Methods of using compounds having certain inhibitory effect to treat cancer are disclosed. More specifically, methods of using myosin light chain kinase inhibitor (MLCK) to treat cancer are disclosed. MLCK inhibitors may cause reduction in MLC-P and induce apoptosis in neoplastic cells and prevent and or inhibit the tumor growth.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080081079 - Portable saline nasal spray: A portable saline nasal spray is a device designed to remove allergens or other harmful substances from the human nasal cavity in effective and convenient way. The portable saline nasal spray includes a spray pump that is operated by a finger, a spray nozzle that is ergonomically designed to effectively... Agent: Byung Kwon Cha

20080081080 - Oil-based skin treatment composition: The invention provides an oil-based skin treatment composition that contains antibacterial zeolite, an oil component, and glutathione and/or L-cysteine. The object of the invention is to provide an oil-based skin treatment composition that is blended with antibacterial zeolite and that has excellent washability when it has adhered to articles of... Agent: Townsend & Banta C/o Portfolio Ip

20080081081 - Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity: This invention includes a composition of Agastache rugosa and tilianin obtained by separation-purification for anti-inflammation and anti-atherosclerosis, and more particularly, an extract of Agastache rugosa and tilianin obtained therefrom by separation-purification which are effective in preventing and treating not only inflammatory diseases but also atherosclerosis related to inflammatory responses and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080081082 - Topical skin compositions, their preparation, and their use: Topical skin compositions include a complex containing components to provide a defense against the various pathway mechanisms of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. The compositions may be administered by topically applying them in an amount to... Agent: In Re: Alticor Inc. 28533 Brinks, Hofer, Gilson & Lione

20080081083 - Methods and compositions for improving cardiovascular risk factors and metabolic risk factors that cause syndrome x: The present invention provides for compositions and related methods using extracts from the Cissus quadrangularis plant to improve and eliminate various cardiovascular risk factors and metabolic risk factors that cause Syndrome X. Controlled university studies demonstrated that 300 mg Cissus quadrangularis plant extract provided to obese humans daily for six... Agent: Greenberg Traurig LLP (la)

20080081084 - Methods and compositions for improving cardiovascular risk factors and metabolic risk factors that cause syndrome x: The present invention provides for compositions and related methods using extracts from the Cissus quadrangularis plant to improve and eliminate various cardiovascular risk factors and metabolic risk factors that cause Syndrome X. Controlled university studies demonstrated that 300 mg Cissus quadrangularis plant extract provided to obese humans daily for six... Agent: Greenberg Traurig LLP (la)

20080081085 - Herbal composition for maintaining/caring the skin around the eye, methods of preparing the same and uses thereof: Disclosed is a novel herbal composition for maintaining/caring the skin around the eye, the composition comprising extracts of Saxifraga ligulata syn. Bergenia ligulata, Cipadessa baccifera and Emblica officinalis and cosmeceutical excipients thereof. Also disclosed is a method of extraction, delivery system comprising the same and use thereof.... Agent: Knobbe Martens Olson & Bear LLP